Discipline in genetics
POPULARITY
Categories
76 episodes with genomic
12 episodes with genomic
15 episodes with genomic
6 episodes with genomic
14 episodes with genomic
11 episodes with genomic
25 episodes with genomic
13 episodes with genomic
9 episodes with genomic
4 episodes with genomic
8 episodes with genomic
4 episodes with genomic
4 episodes with genomic
6 episodes with genomic
4 episodes with genomic
6 episodes with genomic
3 episodes with genomic
6 episodes with genomic
4 episodes with genomic
8 episodes with genomic
6 episodes with genomic
5 episodes with genomic
4 episodes with genomic
4 episodes with genomic
5 episodes with genomic
3 episodes with genomic
12 episodes with genomic
3 episodes with genomic
4 episodes with genomic
4 episodes with genomic
4 episodes with genomic
2 episodes with genomic
4 episodes with genomic
2 episodes with genomic
2 episodes with genomic
12 episodes with genomic
6 episodes with genomic
4 episodes with genomic
2 episodes with genomic
4 episodes with genomic
4 episodes with genomic
4 episodes with genomic
3 episodes with genomic
2 episodes with genomic
3 episodes with genomic
Broadcast from KSQD, Santa Cruz on 8-27-2026: Preparing for extreme heat requires a few days of controlled hyperthermia to boost blood plasma volume and trigger heat shock protein production. Dr. Dawn cites research showing that daily 40-minute treadmill sessions in an 80-degree room followed by 40-minute hot baths for six days—or simply an hour daily in a 40°C bath for four days—produces 75-80% of full acclimatization before a heat-zone trip. Five red flags warrant an ER trip for abdominal pain: pain worsening with coughing or car bumps (peritonitis), lack of gas passage with nausea (bowel obstruction) especially with dark green bilious vomiting, yellowing whites of eyes (bile duct obstruction with sepsis risk), tarry black shiny stool (bleeding ulcer versus coffee-ground vomit), and dizziness with pain (possible leaking aortic aneurysm). Dr. Dawn urges any man who has smoked over 100 lifetime cigarettes to request the Medicare-covered abdominal ultrasound screening for aortic aneurysm, noting only 4% of eligible men currently receive it. Quaternary ammonium compounds (QACs) fill nearly half of disinfectants, surface sanitizers, and cleaning wipes, with use surging after 2016 FDA antimicrobial bans and the COVID pandemic. A 2023 Environmental Science and Technology review documented reproductive toxicity, hormone mimicking, dermal and respiratory irritation, and disruption of mitochondrial oxidative phosphorylation. Dr. Dawn recommends apple cider vinegar and water as a safe household cleaner and directs listeners to EWG.org for QAC-free product listings. A UK Biobank study of 65,000 people born in the 1940s-50s exploited WWII sugar rationing (eight ounces weekly through 1953) as a natural experiment. Those exposed to less sugar before age two had 20% lower dementia risk with 2.5-year delayed onset, and protection held even for those whose low-sugar exposure was purely in utero—underscoring the importance of avoiding added sugars in baby foods during the first 1,000 days. A Coast Guard rescuer's suicide following years of headaches and mood swings prompted his teenage daughter's high school survey of 77 surfmen, most of whom described the same TBI symptoms. Repeated boat impacts hitting waves at 6G at the deck translate to roughly 60G at the sailor's head—more violent than car crashes—prompting the Coast Guard's first official acknowledgment of the wave-pounding brain injury problem. Anopheles stephensi, a hardy South Asian malaria vector that thrives in urban environments and survives dry seasons, has spread from Djibouti (2012) through Yemen, Ethiopia, Sudan, and Kenya. Genomic analysis reveals distinct genetic clusters as it advances, all largely resistant to standard mosquito-control chemicals used in netting and sprays. Dr. Dawn ties this to broader arthropod-borne disease expansion in the U.S. from climate warming, and defends deer culling as tick-vector reduction. Dr. Dawn recommends the PREVENT calculator (using blood pressure, cholesterol, age, sex) as the starting point for coronary risk assessment. Coronary calcium scores are most useful for those in the borderline/intermediate range (3-9% ten-year risk)—a score above age-normal warrants reconsidering statin therapy—but add little value at high risk (where zero calcium doesn't rule out non-calcified plaque) or in older patients. An update on shingles vaccination and dementia: Geldsinger's 2025 Welsh natural-experiment study (exploiting birthday-based Shingrix rollout cutoffs) showed a 20% dementia reduction, since replicated in Canada, Australia, and Scotland. New Hebrew University data suggests giving Shingrix four weeks apart (Dr. Dawn cautions against this shortened interval) may stabilize cognition in existing Alzheimer's patients. The proposed mechanism involves boosting regulatory T-cells that dampen chronic neuroinflammation—also explaining why BCG (400% dementia reduction in bladder cancer patients) and flu vaccines show similar protective effects. An oral KRAS-inhibiting drug, daraxonrasib, doubled median survival in 500 patients with metastatic pancreatic cancer from about six months to 13.2 months by blocking proteins produced by the historically undruggable KRAS gene—the first major advance for a cancer where metastatic diagnosis has meant near-immediate death sentence.
Vigorous Steve, Dr. Dean St. Mart, & Kurt Havens join the chat.APR Health Solutions Peptides: www.aprhealthsolutions.com - code nyleOptimize HRT Clinic: https://members.optimize-hp.com - code nyleMerch: https://www.aykons.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'nyle' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘nyle' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program: https://www.nylenaygafitness.com00:00:00 - Intro00:05:17 - What We Knew Before Our First Cycle00:16:18 - Genomic vs Non-Genomic Steroid Pathways00:22:48 - mTOR, Leucine & Protein Timing00:25:20 - Preserving Muscle & Blocking Cortisol00:28:00 - Caloric Cost of Muscle & Aging00:31:08 - The High Protein Myth on Gear00:36:58 - Kidney Health, Blood Pressure & EQ00:40:47 - Epicatechin, Injectable YK-11 & Inflammation00:45:00 - Mitochondrial Peptides & Leaky Gut00:50:50 - Follistatin & Myostatin Inhibitors00:57:01 - Steroids You Should Avoid01:06:14 - Mental Health Regrets & Tren Aggression01:13:28 - Retiring & Detaching Your Ego01:17:05 - Finding Identity Outside Bodybuilding01:22:36 - Custom Stacks vs Cookie-Cutter Protocols01:30:20 - The Evolution of Safer Bodybuilding01:33:57 - Extreme Fat Loss: ATX-304, BAM15 & DNP01:39:26 - Is Insulin Actually Necessary?01:43:30 - Blood Sugar Myths & Morning Hydration01:53:08 - Growth Hormone: Men vs Women02:00:47 - Hematocrit, Estrogen & Phlebotomy Myths02:12:53 - Injection Frequency & Patient Compliance02:17:52 - GLP-1 Dosing: Retatrutide & Tirzepatide02:28:39 - Peptide Stacks & Intranasal Xenatide02:31:00 - The Ultimate Hair Loss Protection Stack02:41:30 - Final Advice
This bonus content is a reading from Platypus, the CASTAC Blog. The full post by Megan MacGregor can be read at https://blog.castac.org/2026/08/microbiome-monitoring-smart-toilets-precision-medicine-and-the-post-genomic-bowel/. About the post: Imagine that every time you poop, your hygiene routine involves depositing your used toilet paper into a toilet-side receptacle. As you wash your hands, the device mixes, processes, and extracts microbial DNA from your stool. It sequences the microbial DNA for a real-time readout of your microbiome (the microbial genomes from within your gut, or at least the ones that made it to your stool), automatically sending the information to a large-scale microbiome database that integrates it into its data, algorithms, and analytic programs. The program connects to an app on your phone, telling you that based on your personal version of a healthy microbiome, today your microbiome is looking a little low in the bacterial species Akkermansia municiphila and high in some risky metabolites (the molecular outputs of some of your gut microbes).
Dr Mykyta Artomov visits the studio as we consider DNA, genomic research, and privacy. Our genetic information helps researchers uncover diseases and develop new treatments. But DNA is also deeply personal. How can researchers learn from genetic data while respecting and protecting patient privacy? Tune in to find out!
This episode was originally released on August 2, 2022Just like any good superhero comic, we start this episode with the science going incredibly wrong. Think: vats of toxic waste producing evil mutants that ravage the city. Or maybe not so evil. It really depends on your perspective. Just like the X-men, genetic mutations get a bad rap in the public eye. But they aren't all nasty.Dr. Kaylee Byers speaks with data scientist and evolutionary biologist Dr. Brian Arnold on how the genetic ‘mistakes' known as variants occasionally encode incredible abilities. Odd elephants, hiding in our ocean depths, and Rogue-ish bacteria are just a few examples. Dr. Arnold defends these genetic anomalies, and explains how they can make a huge difference to the future of humanity and life on this planet. Also joining us is marine biologist Dr. Maria Pia Miglietta, who shares an incredible ability sitting in our ocean depths. Immortality.So strap on your capes, because we're heading straight into the strange terrain of “heroic mutations.” Listen to Nice Genes! wherever you get your podcasts, brought to you by Genome British Columbia.Resources: Genetic Mutation - NatureGenomic mutation rates: What high-throughput methods can tell usShane Campbell Staton Group - Tuskless ElephantsIvory poaching and the rapid evolution of tusklessness in African elephants - ScienceReal-Life X-Men: How CRISPR Could Give You Superpowers in the Future - synthego.comIndonesian divers have evolved bigger spleens to hunt underwater - ScienceMutations may reveal how Tibetans can live on world's highest plateau - ScienceThe Immortal Jellyfish - American Museum of Natural HistoryCellular reprogramming and immortality: Expression profiling reveals putative genes involved in Turritopsis dohrnii's life cycle reversalTranscriptome Characterization of Reverse Development in Turritopsis dohrnii (Hydrozoa, Cnidaria)Horizontal gene transfer and adaptive evolution in bacteria - nature reviews microbiologyHorizontal gene transfer overrides mutation in Escherichia coli colonizing the mammalian gut - PNASThe Ship of Theseus Dilemma - Open Okstate
A unique team of specialists in data generation and artificial intelligence are co-developing an AI genomic model capable of predicting genomic edits that improve commercial-scale protein production. This collaboration between Triplebar and UC Berkeley—with funding from the U.S. Department of Defense and the National Science Foundation through a BioMADE grant—aims to accelerate strain optimization for more resilient, cost-effective protein manufacturing across therapeutic and industrial applications. In this episode of Off Script, we spoke with Shawn Manchester, CEO of Triplebar, about how the company's ultra-high-throughput microfluidics platform is being paired with UC Berkeley's genomic language model to transform strain engineering. Manchester discussed the motivation behind the collaboration, explained how this genomic language model differs from traditional AI approaches, and explored how they could improve protein expression, shorten development timelines, and reduce manufacturing costs. He also shared his vision for how AI-driven strain optimization could help enable the next generation of protein therapeutics and other biomanufactured products.
The Nurses Report on America Out Loud with Gail Macrae, BSN, RN – Nicholas Rosen, a veteran musician, producer, and music director with credits alongside Prince, Bruno Mars, Imagine Dragons, and many others, founded Reson8 (also styled Resonate) to translate individual DNA patterns into customized musical experiences...
In this new episode of Speaking of SurgOnc, Dr. Rick Greene & Dr. Aatur Singhi discuss the article: "PancreaSeq Genomic Classifier (PancreaSeq GC) Improves Pancreatic Cyst Classification and Detection of Advanced Neoplasia: A Multi-institutional Validation Study" from the April 2026 issue of the Annals of Surgical Oncology.
Leukemia specialist Matthew Connor addresses parsing the genomic determinants of the leukemias for diagnosis, and reviews the mystery of mixed phenotype acute leukemia, a rare type of acute leukemia that expresses phenotypic markers of both AML and ALL. Learn more about Matthew Connor, MD
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most exciting stories shaping the industry right now. Let's start with a groundbreaking advancement in gene therapy. Researchers have achieved a significant milestone by successfully using CRISPR technology to treat a rare genetic disorder in humans. This marks one of the first times that CRISPR has been applied directly to patients in such a way, offering hope for those suffering from conditions previously thought untreatable. This development is not just about treating one disorder; it opens up a world of possibilities for addressing various genetic diseases. By precisely editing genes at their source, scientists are paving the way for therapies that could revolutionize how we approach genetic disorders. Shifting gears to regulatory news, the FDA has granted accelerated approval to a new Alzheimer's drug that targets amyloid plaques in the brain. This drug, through its unique mechanism of action, aims to slow down cognitive decline in patients diagnosed with early-stage Alzheimer's disease. While there remains debate about the amyloid hypothesis itself, this approval signals a hopeful step forward in treating a condition that affects millions worldwide. As researchers continue to explore and understand Alzheimer's pathology, such approvals encourage further innovation and investment into neurodegenerative research. In clinical trial news, a biotech company has announced promising results from its Phase 3 trial of an mRNA-based vaccine for respiratory syncytial virus (RSV). The trial demonstrated high efficacy in preventing severe RSV infections among older adults, a population particularly vulnerable to this virus. These results not only underscore the versatility of mRNA technology but also highlight how quickly platforms developed during the COVID-19 pandemic can be adapted for other infectious diseases. This advancement suggests a future where rapid response to emerging viral threats becomes more feasible. Meanwhile, in the realm of oncology, there's been an exciting development with a novel immunotherapy showing potential in treating pancreatic cancer. This approach involves modifying patients' own immune cells to better recognize and attack cancer cells, a technique known as CAR-T cell therapy. Although traditionally successful in blood cancers, applying it to solid tumors like pancreatic cancer has been challenging due to their dense and protective tumor microenvironments. Early data indicate that this immunotherapy may penetrate these barriers more effectively, offering new hope for patients facing one of the deadliest forms of cancer. On a broader scale, the industry continues to see an increase in collaborative efforts between pharmaceutical giants and smaller biotech firms. These partnerships are essential for fostering innovation and speeding up drug development processes. By combining resources and expertise, companies can tackle complex health challenges more efficiently than ever before. Such collaborations also reflect an industry trend towards open innovation models that prioritize agility and shared knowledge over traditional competition. Finally, let's touch on an emerging trend that's capturing attention: personalized medicine's growing influence on drug development strategies. With advances in genomics and data analytics, pharmaceutical companies are increasingly tailoring therapies to individual patient profiles rather than adopting a one-size-fits-all approach. This shift not only improves treatment efficacy but also reduces the likelihood of adverse reactions, ultimately leading to better patient outcomes and more efficient healthcare systems. These stories illustrate an industry at the cutting edge of science and technology, driven by a relentless pursuit of new ways to improve human health. Each breakthrough not only represents progress but also carries profound implications for future research directions and therapeutic possibilities. That's all for today's edition of Pharma Daily. Stay tuned as we continue to bring you more updates on these exciting developments in pharmaceuticals and biotechnology. Thank you for listening, and we'll be back soon with more insights from this dynamic field.Support the show
In this episode, Herby Lutz, Jersey Development Manager, and Marc Bolen, Dairy Sire Marketing Coordinator, break down the top genomic Jersey young sires dominating today's rankings for HHP$®, JPI™, production, and wellness traits. With 10 of the breeds top 25 HHP$ sires represented, the GForce™ lineup showcases elite genetics designed for profitability, longevity and herd health.
This episode was originally released on November 15, 2022Things aren't always what they seem on the surface, especially when it comes to our oceans. So many mysteries hum below its watery surface. So, you may just have to use your ears when it's too dark to see exactly what's going on down there.Dr. Kaylee Byers looks into the ocean giants that lurk in the depths and the unique songs they share with us. She sits down with whale biologist Dr. Jennifer Allen on how whale songs are imparting a cultural exchange between populations that are hundreds of miles apart. Filmmaker Joshua Zeeman shares his journey to find the infamously dubbed 'Loneliest Whale'. And Paeleobiologist Dr. Travis Park from the Museum of Natural History in London tells us how whales developed their unique singing superpowers by taking us back through millions of years of evolution. Finally, researcher Grace Baer brings us to a remote west coast station studying whale populations and the effects of ocean traffic noise.It's a whale-sized episode taking you on a listening journey into this wonderful watery world!Special thanks to Captain Gaelen Krause of the Island Odyssey, for capturing recordings on his journey to search for whales along the British Columbia coast.Resources:1. Southern Resident Killer Whale Research Project | Parks Canada2. Whales learn songs from each other in a cultural 'deep dive' | phys.org3. Whale-monitoring robots are oceanic eavesdroppers with a mission | Popular Science4. Whale Songs Are Getting Deeper | The Atlantic5. The search for the loneliest whale in the world | The Guardian6. The Loneliest Whale: The Search for 52 | Bleecker Street Media7. BTS (방탄소년단) Whalien 52' MV | BigHit Entertainment7. Watkins Marine Mammal Sound Database | Woods Hole Oceanographic Institution8. Underwater Noise Pollution Is Disrupting Ocean Life - But We Can Fix it | TIME9. Convergent evolution in toothed whale cochleae | BMC Evolutionary Biology10. Evolutionary Basis of High-Frequency Hearing in the Cochleae of Echolocators Revealed by Comparative Genomics | Oxford Academic11. Genome-culture coevolution promotes rapid divergence of killer whale ecotypes | Nature12. DNA Suggests Cultural Traits Affect Whale Evolution | Science13. San Francisco: Dead Whale Opens Seafood Season | Universal International Newswire14. Songs of the Humpback Whale | Roger Payne, CRM Records15. Whaling Commission | Associated Press Archive16. Monaco - International Whaling Commission | Associated Press Archive17. Bubble Net Feeding | BC Whales18. Cool Genomics Facts - Fact 4 & 5: Environmental DNA | Genome British Columbia
What does it take to build the data systems that sit behind your genetic evaluations?This week on the podcast, Ferg catches up with Dan Garrick from Helical. Dan grew up on a sheep, beef and venison farm in the Manawatu before moving to the US at 13, where he went on to complete a PhD in aerospace engineering at Iowa State University. He's the son of Professor Dorian Garrick, one of New Zealand's most respected animal breeding geneticists, and his grandfather was one of the world's leading experts on sharks, making Dan a third-generation PhD.Dan explains how the same maths used to model fluid dynamics around rockets is used to generate breeding values, and how he ended up joining the family business in 2017 to help roll out some of the first production single step evaluations in the US for American Hereford and IGS. That work quickly revealed a major bottleneck in managing the genomic data flowing in from DNA testing labs. That's where Helical was born.Ferg and Dan talk through how Helical now serves breed societies, genetics companies, universities and labs across beef, dairy, sheep, horses, dogs, aquaculture and forestry. They also look ahead at where things are going. From decision support tools and AI in commercial herds, to the potential for wearable devices like virtual fencing collars to generate entirely new breeding values nobody has thought of yet - both Dan and Ferg agree the future is bright for Agriculture. Head Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, Heiniger Australia and New Zealand, and ProWay Livestock Equipment. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out the MSD range HERECheck out Allflex products HERECheck out Heiniger's product range HERECheck out ProWay's product range HERE
Send us Fan Mail Genomic Data Scientist Career Guide: Salary, Scope & Skills in India and Abroad What if you could use DNA data, Artificial Intelligence, and coding to help predict diseases, improve treatments, and shape the future of medicine?Welcome to another future-ready episode of The Kapeel Gupta Career PodShow, where we decode powerful and emerging careers for students and professionals.In this episode, we explore one of the most exciting interdisciplinary careers of the future — Genomic Data Scientist. This is a career at the intersection of:
BUFFALO, NY – May 6, 2026 – A new #casereport was #published in Volume 17 of Oncotarget on May 4, 2026, titled “Small bowel GIST harboring concurrent KIT exon 9 duplication and SDHC mutation: A case report.” The study was led by first author Cameron B. Speyer from the UCLA David Geffen School of Medicine, and corresponding author Joseph G. Crompton, who holds appointments at both the UCLA David Geffen School of Medicine and the Jonsson Comprehensive Cancer Center. In this report, the authors describe a rare and clinically informative case of a small bowel gastrointestinal stromal tumor (GIST) harboring two genetic alterations that are typically considered mutually exclusive. GISTs are most commonly driven by activating mutations in the KIT or PDGFRA genes, which confer sensitivity to targeted therapies such as imatinib. In contrast, tumors associated with succinate dehydrogenase (SDH) deficiency represent a distinct subgroup that is generally resistant to these treatments. The patient, a 68-year-old man, presented with progressive abdominal pain, bloating, and constipation. Imaging studies revealed a large heterogeneous mass in the lower abdomen measuring up to 18 cm. A biopsy confirmed a spindle cell neoplasm consistent with GIST, with immunohistochemical staining positive for CD117 and DOG1. Genomic analysis identified both a KIT exon 9 duplication (A502_Y503) and a germline SDHC mutation (p.R50C)—a highly unusual combination. Despite the presence of the SDHC mutation, which is typically associated with resistance to therapy, the patient demonstrated a strong response to high-dose imatinib. After six months of neoadjuvant treatment, imaging showed a marked reduction in tumor size and metabolic activity, enabling successful surgical resection. “This case suggests that oncogenic KIT signaling may remain the dominant driver of GIST behavior despite the presence of a germline SDHC mutation and highlights the importance of integrated molecular interpretation in GIST management.” Pathologic examination of the resected tumor revealed significant treatment response, including extensive necrosis and reduced tumor viability. Notably, immunohistochemistry demonstrated retained SDHB expression, indicating preserved SDH complex function despite the identified germline mutation. The case highlights an important clinical insight: not all detected genetic alterations contribute equally to tumor behavior. While SDH-deficient GISTs are typically resistant to imatinib, this tumor behaved in a manner consistent with KIT-driven disease, underscoring the importance of interpreting molecular findings within their clinical and pathological context. Overall, this report emphasizes the need for integrated molecular analysis in cancer diagnosis and treatment. As next-generation sequencing becomes more widely used, clinicians may encounter tumors with multiple coexisting mutations. Determining the dominant oncogenic driver is essential for selecting the most effective therapy and improving patient outcomes. DOI - https://doi.org/10.18632/oncotarget.28863 Correspondence to - Joseph G. Crompton - jcrompton@mednet.ucla.edu Abstract video - https://www.youtube.com/watch?v=eB_QG2vBNCE Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, GIST, KIT duplication, SDHC mutation, genetic testing, case report To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
In this episode, we celebrate 10 years of the Participant Panel and explore how genomic research is being guided by patient and participant voices. Made up of people who have consented for their genome, or the genome of their loved one, to be included in the National Genomics Research Library, the Panel plays a vital role in shaping how research is designed, how data is used, and how genomics is communicated. From influencing policy discussions to to advising the Genomics England board, their work helps ensure lived experience is embedded from the very beginning. Over the past decade, the Panel has driven meaningful change. From advocating for greater transparency and accessibility, to challenging how the genomics community talks about genetic conditions. But beyond the impact, this episode focuses on the people behind the work: their motivations, experiences, and the realities of representing a wider community. Our host, Sharon Jones is joined by: Kirsty Irvine – Chair of the Participant Panel and member of the NHS Genomic Medical Service People and Communities Forum Lisa Beaton - member of the Participant Panel, panel member for the North East and Yorkshire GMSA and research and development for Harrogate Hospital Foundation Trust Frances Allan – member of the Participant Panel and member of the following: CRUK Women+s Cancers PPIE at Cambridge MHRA Yellowcard Biobank Northumberland NHS health forum Ovacome Healthforum IMPRESS cancer diagnostic tool study participant You can find out more about the Participant Panel in our recent Genomics 101 episode which Lisa featured in, titled ‘What is the Participant Panel?', and you can read about their timeline of achievements over the last 10 years. “One of the things as participants that we're always really keen to get across, particularly to the scientists, is that behind every piece of data is a face and a name” You can download the transcript, or read it below. Sharon Jones: This time on Behind the Genes, we'll be celebrating the 10th anniversary of the Participant Panel, and we'll discuss how genomic research is being guided by patient and participant voices. The panel is made up of participants whose data is held in the National Genomic Research Library. They help us to put lived experience at the heart of our work. My name is Sharon Jones, and in this podcast we cover everything from cutting-edge research to real-life stories in genomic healthcare. Joining me this time are Kirsty Irvine, chair of the Participant Panel, and Frances Allan and Lisa Beaton, who are also both members. Collectively, they wear many hats for a range of organisations, which are listed in the episode description. As you'll hear, this one is all about people power. So back in 2016, the Participant Panel was in its infancy, with 12 founding members bringing lived experience of rare conditions. The idea was straightforward but radical: that the people whose genomes were being sequenced should have a real say in how the work was done. Over the decade since, the Panel has shaped some significant changes, from pushing for a service that let participants track their own samples, to publishing a language guide that changed how the genomics community talks about genetic conditions and disability. They've navigated the pandemic, welcomed new members and, in 2025, launched their first formal strategy. This year they mark their 10th anniversary, and today we're hearing from some of the people who've been part of that story. So welcome Kirsty, Frances and Lisa. So what was your reason for joining the Participant Panel? And I will ask Frances that. Frances Allan: Hi Sharon. I joined the Panel back in 2023 following a cancer diagnosis, and as part of that investigation I was fortunate enough to have a whole genome sequence performed. And they also asked would I be interested in taking part in a panel who look after this information, and I ticked the box and then thought no more of it. And then a month or so later I heard from the then Chair, Jillian, um, and had a chat about genomics and joined the Panel, and it was a very good decision that I made. Sharon Jones: Did you have any kind of expectations? What were your early thoughts when you kind of accepted? Frances Allan: Not many thoughts. So I was in the middle of my chemotherapy treatment, but one of the things that really stood out: when I signed the consent form, I said, well, of course I would do that. And the clinician consenting me, said, actually, not everybody does. And I thought, well, why would they not want to do that? So I was really interested in finding out about that. I had no idea how influential the Panel was, and that was great to discover as I became part of it. But seeing the breadth of the research and the knowledge already gained, compared to my rudimentary A-level Biology from many, many years ago, gave me incredible hope, um, and really helped me through a very difficult, difficult time. Sharon Jones: Yeah, that's, that's amazing. It's amazing that you could kind of think in that way whilst you were actually going through the treatment itself. I mean, how did you split yourself in that way? Frances Allan: I think it gave me a sense of, of purpose. So at the time, I'd, I'd stopped working to have my treatment and I was a, a vet previously, so I was used to thinking about medical things and problem solving, and it, it filled a, a void in my life. I had no idea I'd be able to contribute to it. I thought, well, I'd learn something from it. But, you know, the, the Panel is managed very well. Kirsty's a fantastic Chair. Everybody gets an opportunity to speak, and the attendance can be in person. And I've done most of them in person. When I was poorly I attended an online meeting, but even that is managed so well that you get a chance to speak up. If you're not feeling well enough, then you can, you can add it to the chat or email. So it's very, very inclusive and a very supportive environment, as well. Sharon Jones: Yeah, it sounds like a, a very safe space to be in. And Lisa, what was your reason for joining the Participant Panel? Lisa Beaton: I think it was sort of one of those, bit of a light bulb moment for me thinking, yeah, I could do that. I'm not quite sure why I felt I was qualified to do that, but my reasoning is slightly different than Frances. So I joined the 100,000 Genomes Project back in 2015 in respect of one of my children who has an undiagnosed, thought to be neuromuscular, syndrome. Um, so myself, my husband and our daughter recruited for genetic sampling, and over the years I've sort of taken a keen interest in all things genetic and genomic related, followed on kind of various social media platform. And I think if memory serves, I saw an announcement or an advert stating, do you want to be part of the Participant Panel, clicked on the link and thought, this is something that really resonates with me. I've served with different hats on different kind of participant groups and speaking events, and it's something I feel really, it's an overused phrase, but I do feel really passionate and strong about it because, you know, we are the people who are the front and centre of this, because it's our genetic information. So I applied, did a bit of a kind of resume of myself, um, then had huge imposter syndrome and thought, oh, that'll be the last I'll ever hear of that. And uh, actually had a really lovely interview with some of the then, uh, members of the Panel and must have said a few of the right things, 'cause here I am, three years down the line. Sharon Jones: That's amazing. Has it lived up to your expectation? How has it, how has it helped you get through what sounds like a really challenging time? Lisa Beaton: It's, it probably sounds wrong to say I, I didn't really have an expectation, but I joined it really just wanting to kind of know more and see if I could find out more details, more information, kind of more genomic discovery, and hope that I could give something back, if that doesn't sound too cringey. I think one of the things I'm always really keen to say is that you don't need to be a geneticist. You don't need to be a scientist. You don't need to kind of have lots of scientific information. And I will confess that the very first meeting I went to, I did come away thinking, I think I probably only understood about one word in three. But three years down line as I say, I'm still here, and it's been good to challenge myself and to explore kind of things that I don't know information about, but also I found that there are areas that I can definitely bring lived experience to and, and hopefully a voice for people like myself and my family. Sharon Jones: Yeah. That's so important. It sounds like you've become a bit of an expert by, uh, experience there. Has your vocabulary improved in the last three years? Do you know more words now? Lisa Beaton: Yes. Uh, I've, I have to remind myself not to use an acronym. It's one of my pet peeves. You know, when you're, you're in a, a meeting and terminology or, or vernacular, that is not necessarily something that people would use day-to-day, and I think lots of you know, you don't, don't have to be genomics or genetics to, um, using acronyms for things. It's something we all need to remind ourselves that just because you know that expression, somebody else doesn't. So it's really important to kind of keep that at a, a lay explanation so that everybody understands it. Um, I think particularly with quite heavy subject matter such as genomics and genetics, there can be a tendency otherwise for people to feel that it's not for them. And of course it is, because it's about our own personal data. Sharon Jones: Yeah, absolutely. And, um, and coming to you, Kirsty, what were your kind of motivations for, for joining the Participant Panel? Kirsty Irvine: Well, it's been quite a long journey for me to find myself on the Participant Panel, so I and my family, we were all consented into the a 100,000 Genomes Project back in 2015. But from that point, I then spent nearly 10 years chairing committees at NHS Digital and then NHS England, focusing on health data access. And I remember talking about the 100,000 Genomes Project at my interviews for those roles. I then went down a different path. And in those roles I was very much wearing my solicitor's hat. So I was thinking about governance and risk and were we complying with the precise wording of the legislation. And then when the chair role came available, I had a number of people sort of forward it to me saying, I think this would suit you. I think this would suit you. And at that stage, I was aware of the Panel because I'd met the fantastic former chair, Jillian. Um, so I'd seen Jillian at various conferences and meetings and things, so I was well aware of what the Panel did. I was well aware of the Panel's standing. It was probably the only participant panel that I was aware of in my work with NHS Digital, NHS England. And then I realised, you know, I wanted to be closer to the people behind the data and I wanted to do something more active. I wanted to bring a bit more of myself. Because when you're chairing a very formal committee, at NHS England, you, you can't talk about the time that you resuscitated your child at home, you know? And on the Panel, you know, my very first meeting, I, I met someone, someone whose child had, you know, been fed with an NG tube for a number of months. You know, I met someone else who had resuscitated their child, you know, and all of a sudden I could bring more of myself to my colleagues and, and find a real community. So for me, joining the participant panel was a way of shifting the perspective, but to also bring that experience with me because I, the roles at NHS England, you know, from a governance perspective, I couldn't continue chairing those, you know, board subcommittees forever. But I didn't want that knowledge to just sort of disappear. So for me, I'm really delighted that I've, what I hope, what I hope is a good fit. I feel it's a good fit. So that, that's been my journey to the Panel. Sharon Jones: Yeah, that's, that's so interesting. And I guess having that space to kind of be yourself, and having understanding because of your lived experience, brings a lot of value to the role that you're doing now in a way that kind of is different when you're in your previous roles of NHS Digital, because you had to be a bit more, kind of stand back from it and, yeah. That's so interesting. So, what has it been like being part of these groups? You know, the ones that you kind of, you're involved in a lot of things, and we'll list them in the, in the web description. And how has it kind of affected your life, essentially, because it's not the kind of average thing that people are involved in. Frances Allan: So it's been an incredible, I think as Lisa alluded to, incredible learning curve. We've learnt so much. But the team at Genomics England are endlessly patient and very skilful at passing that information on. And we have access to the leading researchers, the clinicians that are involved in genomics. And they're happy to take any question. And the questions, however silly, there's no silly question. They're happy to answer that. And so we learn every time we attend a meeting, we have quarterly meetings and that can be in person or online. Um, but we also have regular lunch-and-learns. So if there's somebody we want to speak to or find more about their specialist area, they'll come and have a, a chat with us. And then we have half of it, them chatting to us and half us, us. Us asking them questions and, and challenging them. Um, so it's very, very informative and then learning from each other. And as Kirsty was saying, you know, this is a, a group of people who've, who've dealt with an awful lot of unique situations and they're happy to, to share that and pass on the information. It's a, it's a great place of learning. Sharon Jones: Lisa, would you agree with that? How it been for you? Lisa Beaton: Yeah, I would definitely echo everything that Frances has actually said there, and I think it's a very humbling experience, as well. Ostensibly, we are a, a collection of individuals who have all been brought together, um, purely because of, uh, our genomic interests. And whether that's for our families, you know, as, as parents, as in my case, or in somebody like Frances' case, who's obviously a participant in her, in her own right. And although there are kind of many differences in our stories, there's also a lot of similarities. But I think what's really interesting, very precious, is that the staff at Genomics England, obviously they range from, you know, there, there's so many different kind of areas from the, the comms, the scientists, etc., but everybody is really interested. They want to know your story, who you are, why you are there. There's a real kind of inclusion focus on that. And one of the things as participants that we're always really keen to get across, particularly to the scientists, is that, you know, behind every piece of data is a face and a name. And I think they really make that felt when they're chatting to us. You know, we go in and, and there, there's people who are there from governance sides for how the data is accessed by other parties. There's people there who are the science technicians, etc. There's people who are dealing with the administrative side of things, but every single person that I've encountered wants to know more about you, what you are there for. And that is, is very, very precious. And as Kirsty also alluded to, a lot of us have been through some really quite traumatic experiences. It, it's not my place to speak of others' journeys, but you know, there, there are, uh, bereaved parents and family members among us. And so we are sharing very precious raw material, emotions, experiences, and that is very powerful, as well. And I, I think the Genomics England staff never forget that. They seem to bear that at the forefront of their, their communications with us, always. Um, and certainly Kirsty and Adam and previous chairs, uh, of the panel, that inclusivity was entirely throughout every dealing we had with them. Sharon Jones: It's very humanising and I think that it's humbling for us who work here that that's always at the forefront of our mind, that this is why we kind of get up and go to work every day, because of that human element. And it's not just a data point. There is a whole family, a story, a history, and that's, that's so important to us in the work that we do. Kirsty, did you want to add your point on this as well? Kirsty Irvine: I've probably got two points I wanted to raise. One was just to draw out what Lisa was saying, is that it can be complex being a Panel member, because the story you're bringing often isn't just your own. In my family, we've got a real, we've got a whole range of genetic differences and conditions that, you know, across the extended family. And so when I speak, I'm often drawing on experiences that aren't solely mine to share, and, you know. So I think that's something that for some on the Panel, we're sort of, we're, we're being quite careful to think about what we're saying, and if we're speaking in the public domain, we might be talking about it in more general terms. So that's, you know, but there's not a single right way, and there's room on the Panel, everyone, for the people who can and, and as Lisa talked about, you know, the, the most acute situation is where someone's bereaved, you know. And it's, so everyone's got different, you know, different experiences. But that, that, again, coming back to the positive side of things, one of the biggest things to me about being on the Panel, what it means to me, is being part of a wider community. I mean, one of the other things that, Sharon, I don't know if I can sort of segue onto this about, you know, the opportunities that have arisen? Sharon Jones: Yeah, absolutely. I'd love to hear more about that. Kirsty Irvine: So one thing that really stands out for me was the opportunity to speak directly with, um, Associate Health Minister Ahmed about, and his policy team. So we went to the department, Adam and I went to the Department of Health, and it was about the use of GP data in consented research cohorts. So getting the GP data into the National Genomic Research Library. So even though there's consent, up until now, that GP data, that tranche of really rich data, hasn't, hasn't gone into the NGRL. So I'll use that abbreviation now that I've used it in full. And so what was really unique for me was that I'd seen it from multiple angles because I'm participant in the 100,000 Genomes Project, so I'm a cohort member. I then worked on the consent review for NHS England. I then sat on a, the consent review assessment committee with, you know, a multiparty group. And then, because I was on the panel, I got to see things full circle. I was then invited to, to go and meet with, um, Minister Ahmed and, and advocate for the use of this GP data. And that really matters because something, you know, there's such important information sitting in that GP data and it wasn't a given, it was not a given that the government was going to the direction that allowed that data to go into the NGRL. And so we were able to talk about how we really wanted that data to be used. And now, going forward, you know, something as simple as BMI or for example, if a, if an individual's coded for a neuro, neurodevelopmental condition like autism, sometimes that data actually only sits in the GP health record. It's in primary care only, so it's not necessarily in the hospital records or other records. And so this is really, really valuable data for, for researchers. And so that was something that was a really special experience, just being able to see that come full circle. And I felt like it's a really tangible example of how the participant voices really helped strengthen that conversation, you know, with the DH policy team, you know, and the government ministers. Sharon Jones: Yeah, I mean that's, that's really powerful and it, it just sort of shows how these opportunities can arise from being involved in a participant panel in a way that you wouldn't have necessarily had that power if you hadn't been involved. And you know, obviously you are wearing lots of different hats in that, in that position, Kirsty. And um, it just sort of shows what can be done when you're, unfortunately, you know, you're in this group for a reason and it's not necessarily the, the most cheeriest reasons, but it, you still leverage that opportunity to create something positive, you know, with it. Frances Allan: So we've given all sorts of opportunities and we seek to get involved with as many things as we can to speak and have our voice heard. Um, and one of the things I did last year was, um, do a short presentation to open a stage at the Genomics England Research Summit, which was quite a challenge for me, but I felt very exhilarated having done it. And then a couple of people came up afterwards and just said, oh, thank you for sharing your story. And a researcher who was slightly older than I, so very experienced, been in his field a long, long time, and he said his clinical years were long behind him, and now he researches within a lab. And actually for someone to say, you know, thank you for, for looking, thank you for finding, had a very profound experience on him. And he knew there was a clinical benefit; his research was very clinically led. But he said he hadn't thought about the recipients of those findings. And I pointed out every time you have that chat with somebody, come to an event like that, have a network, spend a bit longer in the lab, look for something that you might not find, even if it's a negative finding, there will be somebody eventually that benefits from that. And I've been a direct recipient of other people putting forward their whole genome sequence, and then a common change was noted in people with the type of cancer that I have, and that then qualified me for a treatment that otherwise I wouldn't have been eligible for, and I wouldn't have been, I wouldn't have been here now. So it's a very, you know, profound thanks to all the people that are involved from everybody within Genomics England, all the researchers, all the other patients that speak up. We each have a contribution to make. Sharon Jones: Yeah, that's amazing. That must have been quite a poignant experience when you, you met him at the, um, Summit, of just kind of the other side of the, the world that you don't often see. And they obviously don't see our side of the world, and it's kind of interesting to join those dots and kind of come full circle. So moving on. In terms of like, collectively, there's a lot of impact that you have and there's a noticeable shift in organisations where people with lived experience are playing, you know, a much bigger role in decision making. Can you help our listeners understand how people are getting involved in governance and shaping research? Lisa Beaton: From my perspective, it comes back to that word "embedding". I think historically, perhaps there's been an, an almost about-face. Um, it's kind of come at it very backwards, that that embedding has almost happened as an afterthought, which is sort of a bit of a misnomer way of explaining it. When you're talking about embedding, obviously it should be the foundation. Historically, at least both from the parent, parental perspective, I've seen that with clinicians, for example, that historically I've been made perhaps to feel a bit of a thorn in someone's side, that even though we're there for an appointment about our young person, when I'm asking questions that they don't necessarily want to answer, you know, I'm almost the, the add-on rather than the reason that we're there. And I think there has been a paradigm shift in everybody's approach to that. So thinking much more about, you know, the, the what's, the wherefores, the whys. How do we ensure that right from the get go, that patient or participant voice is heard, and it shapes the question. And one of our other Panel members frequently uses the phrase, "nothing about us without us", because that is front and centre of why, you know, genomics exists in the first place, really. Without that data, the conversation ceased to exist. It, it's so vitally important, not just for us as an individual, not just for our family members, but for the greater good, if that doesn't sound too grandiose. Sharon Jones: No, not at all. And, and, and Frances? Frances Allan: I think having raised that value of patient advocacy: what we have to say. So it started off, people felt that they should have some, so they included it, but actually once they started to include it, they thought, this does contribute to our study. And starting at the very beginning of the research project, so what is reasonable to ask participants and patients to do? Is it something that there is benefit from? And trying to see that end goal right at the beginning. And we might help shape a research study that actually goes in a beneficial direction, rather than the researchers starting alone, and then actually getting into the study, and the procedure is, is too painful to endure, there's no clinical benefit, it's not something that can be translated into clinical practice, and it gets abandoned. So start us right at the very beginning, and our perspectives may not be what, what researchers or clinicians think. Uh, with that lived experience, however empathetic you are, the lived experience is a very unique lens and position to look from. Sharon Jones: Yeah, it absolutely is. So, given that you are part of a small group and you know, you're representing a much wider community, essentially, like, what are the considerations that you, you have to bear in mind? Lisa Beaton: I think we can only speak, obviously, to our own individual experience and we are very aware that, you know, diversity, ethnicity, inclusion is something that is a much bigger conversation and certainly something that we want to broaden in, in the panel itself. And I know there's kind of lots of work and thought going into how that can widen those perhaps more diverse communities that historically... It's not that, there's, there's been a terminology that, you know, they're difficult to access, but actually the question is wrong there. The statement is wrong. It's not that they're difficult to access, it's just that we've been asking that incorrectly. And we need to ensure that they are, uh, empowered to bring their stories forward and find ways to push forward for their inclusion. We need to ensure that everybody's voices are heard, otherwise the data set is wrong from the off. So I think that's something that we're all very minded when we speak about, and definitely want to, to diversify the pools of data that come in. That, that has huge resonance for, you know, shaping genomic and genetic policies moving forward, for sure. Sharon Jones: Yeah, definitely. Frances, sort of broadening out that question. Does it feel like a lot of pressure and a lot of responsibility, kind of representing, you know, in this kind of small group where you are almost speaking on behalf of, you know, a lot of people? Frances Allan: I think it mainly feels like a, a privilege, Sharon, to be in that position, to have a say. And back to my, one of my motivators for joining is why would people not choose to do this? And actually understanding why that is. And is it the, you know, the lack of knowledge of genomics? And there is a lot of, of fear about what can be discovered. But understanding the immense benefits from that so people don't miss out on those opportunities. Our genomes contain the, the blueprint to us, but also how we would respond in certain situations, and you want everybody to be using those leverage points. You know, cancer's a really difficult disease to manage, and anything you can do to make it slightly easier, slightly more comfortable, slightly more successful, we want to do that. So every time we speak out and we advocate for the benefits of genomics, we might gain one more person who's going to feel that a successful outcome. Sharon Jones: Yeah, and who knows what, what that can mean for their family and, and sort of further down the line. So have you got any advice for, or encouragement, or any tips for, you know, potential participants who are thinking of getting involved in, in groups? You know, it doesn't necessarily mean the Participant Panel, but just generally, sort of groups related to their conditions or their family's conditions. Frances Allan: Yeah, I think the value of the one's personal experience: don't underestimate that. Everybody has an individual journey and they can comment and reflect on that. And anybody interested in, in joining our panel, you can include in the, the copy or description, ways they're getting in touch with us and speak to us about what that, what that involves. And uh, Lisa said at the, the beginning, you come and it's a huge learning curve, but there are people to support you and guide you through that way. And the learning is, is just fascinating. And there's a position for everybody and everybody's point of view to be heard, and you will be heard. Sharon Jones: Thank you. Lisa? Lisa Beaton: Yeah, I think I might steal a phrase or two actually from some, uh, well-known brands. But, um, one would be "just do it" and the other would be "feel the fear and do it anyway" because, you know, you are amongst friends, first and foremost. We all, we do tailor our experiences, and clearly we self-censor at times because that's necessary to protect the privacy and dignity of not necessarily ourselves, but as we've already alluded to in our chats, but you know, our family members, the wider people that you are aware will be hearing this. And you don't necessarily want certain medical information about your family members out there, because it's not your information to share. But in terms of joining the panel and, you know, having a voice, giving more voices, giving more diverse data, we, we need as many people as possible to come. We need more voices. We need to get our genetic, genomic information out there, uh, in front of the researchers and, and all involved with Genomics England, um, and other patient advocacy groups, as well, because that will only benefit the greater public. Sharon Jones: Thank you. And Kirsty? Kirsty Irvine: I'm just thinking about sort of general tips building on what Lisa and Frances have said. You don't need to be a seasoned public speaker. I think that's something, absolutely not. We've got some fantastic speakers in the group. Um, but then we've got people in the group who've got, who have got different skills, so don't think that you need to be ready to give a TED Talk at the first meeting, be that the Participant Panel or whatever group you might be motivated to join. We, we just need good listeners. I've chaired meetings in the past where people, uh, wanted to contribute via the chat function, and that worked absolutely fine. They would put their incredibly insightful, erudite comments in the chat, and then I would relay them to the group, and that was how we got that person's input, because we realised that they weren't necessarily going to speak up in the forum. So whatever your communication style, we can accommodate it at the Participant Panel and we would be delighted to hear from you. Sharon Jones: That's great. Thank you. Um, final question. So what do you hope the next 10 years of participant involvement will look like? Kirsty Irvine: I think if I could use a little catchphrase, which I'm sure is not mine, but I would like to see us fully integrated as partners, not participants. I'll put that out there. I mean, Sharon, I wonder if I could sort of also open things up to how are things going to look in another 10 years, because there's been some statistics that have really struck me, uh, at presentations that, that we've heard. One of them being that in the next, you know, within 10 years, around about half the data in the National Genomics Research Library will be from, I don't know if this is the best name for it, the general population. So that's people who aren't necessarily seeking an answer, or have a diagnosis or a condition. These are people who have donated their genomic data through being part of, you know, research projects. And, as a panel, so Genomics England's evolving and the panel will be evolving. And in 10 years time, the panel will need to be, I believe, true to the original route. So, 100,000 Genomes Project. Uh, the people who've had their whole genome sequencing through cancer diagnoses. You know, there's a significant COVID cohort, but also people of the gen, general population. So how do we advocate for and look after everyone in that broad group of people. So I think that, that's both a challenge, that's a challenge for us, but it's also really exciting to think how we can meet that challenge. Sharon Jones: Yeah, definitely one, definitely an opportunity and a challenge, and one that will take a lot of thinking in the next few years. Frances? Frances Allan: Yeah, thanks Sharon. I think looking forward to that, that 10-year period is how genomics just becomes a normal part of everybody's healthcare, so we all fully understand the benefits of it. People are willing to participate in it and then using lots of different types of data to go into the National Genomics Research Library. So at the moment, it's mainly genomics material, but there's been a lot of work done with the cancer cohort, putting in diagnostic images, pathology slides, other clinical data, written notes, and this can then be accessed under the strict criteria of the access review committee. It can be accessed by clinicians, researchers across the world. And we want our research library to be the premium source of that information and to have collaboration with researchers, clinicians, participants, worldwide, to speed up the generation of that information and those positive outcomes. It's a, a very, very rich data source now, and it'll only get bigger as we include people from the general population. Sharon Jones: That'd be amazing and have some quite incredible global, um, outcomes. Lisa? Lisa Beaton: I just had a little image actually pop into my head that I, I almost look at it a little bit like we're doing one of those, I think they might be called an "impossipuzzle" where actually we don't have the picture on the box, but we have lots and lots of little pieces that are all going in together and they're making up a really creative, wonderful, fantastic, woven story, a tapestry as you were, of different information that's coming through. And how incredible, you know what, what a wonderful legacy we're building, you know, and this amazing picture that's going to evolve and change and develop over the years to come. Sharon Jones: That's a wonderful note to end on, so we're going to wrap it up there. Thank you for listening. A special thanks to our guests, Kirsty, Frances, and Lisa, for joining me today as we discussed how lived experience can shape health research. If you'd like to hear more like this, please subscribe to the Behind the Genes on your favourite podcast app. And if you want to know more about the Participant Panel, you can head to the Genomics England website and listen to our 10-minute explainer podcast, Genomics 101. Behind the Genes is produced by Deanna Barac, Florence Cornish, Sophie McLachlan and Dave Howard at Bespoken Media.
Learn how AI and whole genome sequencing are transforming rare disease diagnostics, reducing the diagnostic odyssey for families and enabling faster, more accurate clinical decision-making. This episode was recorded live at Becker's 16th Annual Meeting on April 15, 2026.It features insights from Dr. Shannon Haymond, Chief of Pathology and Laboratory Medicine at Ann & Robert H. Lurie Children's Hospital of Chicago and Vice Chair for Pediatric Pathology at Northwestern University Feinberg School of Medicine and Dr. Calum Yacoubian, Director for Health Data Enablement, Applied AI Science, IQVIA. This episode is sponsored by IQVIA.
How do public health officials detect emerging viruses before they spread widely across the U.S.? Heather Reese, Genomic Epidemiology and Preparedness Team Lead at CDC tells us about the Traveler-Based Genomic Surveillance (TGS) program: a cutting-edge effort that turns international travel into an early warning system for public health threats. By combining voluntary nasal swabs from incoming travelers with wastewater sampling from aircraft, the program monitors for pathogens like COVID-19, flu, and RSV. These data help identify new variants and emerging strains, often before they begin circulating domestically, giving public health leaders critical time to prepare and respond.Driving Impact with Flexible FundingHow Public Health Can Support Modern Administrative Readiness in a Dynamic World | ASTHO
Send us Fan MailIn this episode of The Oncology Journal Club, the team weigh promising trial signals against the level of evidence needed to change clinical practice. From perioperative cholangiocarcinoma to molecular matching and chrono-oncology, the focus stays on a key question: what meaningfully improves outcomes for patients?What's covered NeoGOLP trial in high-risk resectable iCCA: improved event-free survival; overall survival still immature MoST programme: molecular matching and survival associations when therapies align with biomarkers Genomic therapy matching in clinical decision-making Chrono-oncology: does treatment timing influence outcomes? CHOPIN phase II uveal melanoma trial: combination therapy signals and feasibility ASCO living guideline updates across lung, gastro-oesophageal and thyroid cancers The Oncology Journal Club Podcast hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson, and proudly produced by The Oncology NetworkVisit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information.
Genomics of the Golden Horde Science Sessions are brief conversations with cutting-edge researchers, National Academy members, and policymakers as they discuss topics relevant to today's scientific community. Learn the behind-the-scenes story of work published in the Proceedings of the National Academy of Sciences (PNAS), plus a broad range of scientific news about discoveries that affect the world around us. In this episode, Ayken Askapuli explains genomic insights into the ancestors and descendants of the Golden Horde. In this episode, we cover: •[00:00] Introduction. •[00:56] Population geneticist Ayken Askapuli introduces the Golden Horde. •[02:01] He describes the individuals in the mausoleums whose DNA the team sampled. •[04:11] Askapuli explains findings about the modern populations the Golden Horde individuals were related to. •[05:08] He then explains findings about the Y chromosome characteristics of the Golden Horde individuals. •[06:14] Askapuli talks about what the results say about the ancestry of the Golden Horde. •[06:48] He describes how the results aid understanding of population genetics in central Eurasia. •[08:10] He lists the caveats and limitations of the study. •[09:53] Conclusion. About Our Guest: Ayken Askapuli PhD candidate University of Wisconsin-Madison View related content here: https://www.pnas.org/doi/abs/10.1073/pnas.2531003123 Follow us on Spotify, Apple Podcasts, or wherever you get your podcasts for more captivating discussions on scientific breakthroughs! Visit Science Sessions on PNAS.org: https://www.pnas.org/about/science-sessions-podcast Follow PNAS: Twitter/X Facebook LinkedIn YouTube Sign up for the PNAS Highlights newsletter
Matters Microbial #127: Even Your Navel Has Them — An Archaea‑Whisperer Explores April 7, 2026 Today Dr. Nahui Medina-Chavez, postdoctoral scholar in the Travisano laboratory at the University of Minnesota, joins the Quality Quorum to discuss her interest in the ubiquitous archaea, and her own research studying experimental evolution in extreme halophiles. Host: Mark O. Martin Guest: Nahui Medina-Chavez Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode Here is an article on R2A, which is used to cultivate water associated microbes. A solid and clear article describing the "great uncultivated majority." An article describing the discovery of the archaea. An engaging video summary of the archaea. A recent article suggesting that archaea are the root and originator of eukaryotes like ourselves! An interesting video about the lokiarcheota, which contain the genetic echoes of eukaryotic life. An article about the extremely halophilic archaea. Do extreme halophiles live within salt crystals? The beautiful pink pigment, bacteriorhodopsin, associated with these archaea (despite the "bacterio" portion of the name). The LTEE experiment, describing how researchers can study evolution in the laboratory. Genomic islands in microbiology. The "Archaeal Power Hour" website. A fine video presentation by Dr. Medina-Chavez on archaea. A fine article by Dr. Medina-Chavez and her postdoctoral advisor Dr. Michael Travisano on archaeal communities. Dr. Medina-Chavez's Research Gate website. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com
This episode was originally released on November 5, 2024Dr. Hannah Belcher was already studying autism she found out she herself was Autistic. Getting her diagnosis felt like everything suddenly clicked… but why did it take so long to get answers?In this episode, Hannah shares her journey and talks about how many Autistic people, especially women, learn to mask their true selves to fit in– causing them to slip through the diagnostic cracks. Then, we invite Dr. John Constantino to break down the genetic underpinnings of Autism Spectrum Disoder and related conditions like ADHD—and how science is shaking up the genomic picture of what we thought we knew about this male-female bias.From outdated theories to “refrigerator mothers,” join hosts Dr. Kaylee Byers and Dr. Rackeb Tesfaye as they comb through the tangled web of sex bias and ask whether our current methods of studying neurodiversity is actually addressing the questions the people with ASD want answered?A Note on Language:When talking about Autism - semantics matter. So, it's important to recognize the nuances of language. Many people in the Autism community prefer identity-first language, such as "Autistic person," as it centers Autism as a core part of their identity. Others, however, may prefer person-first language, like "person with Autism," which places the individual before the condition. We've used both forms of language in this episode, and we encourage respecting individual preferences by asking what each person is most comfortable with. For more on this, check out resources like the National Institutes of Health's guide on writing respectfully about identity and the Autistic Self Advocacy Network's explanation of identity-first language.Additionally, when we refer to ‘Autism risk' in the context of academic research, it typically means an increased genetic likelihood of receiving an Autism diagnosis. However, we recognize that "risk" can imply a negative connotation (which we do not support.) Instead, we aim to discuss Autism in ways that honour the neurodiversity of all individuals.Lastly, regarding sex differences in Autism diagnoses, in this episode, we're talking specifically about sex assigned at birth. Although we mention gender, we want to be clear that we aren't exploring how Autism diagnoses may vary by gender identity—that area remains understudied! So, our conversation is focused on differences between males and females, and we look forward to seeing more research on the richly complex interactions between gender identitiy and neurodiversity in the future.Highlights:(6:32) Growing up undiagnosed(18:52) The genetic underpinnings of Autism and related neurodiverse conditions(22:20) Debunking the “female protective effect”(26:37) A biased assessmentResources:1. ‘Taking off the Mask: A Practical Guide for Managing Autistic Camouflaging and Mental Health‘ - Dr. Hannah Belcher2. Inherited Risk for Autism Through Maternal and Paternal Lineage - National Institute of Health3. 'Decade of data dents idea of a ‘female protective effect'- The Transmitter4. How ADHD Gender Bias is Slowly, Steadily Harming Females - ADDitude Mag5. Refrigerator Mothers - A Discredited Cause Of Autism- Autism Help6. Study challenges idea that autism is caused by an overly masculine brain- Science.org7. Autism Spectrum Conditions In Women: Diagnosis, Mental Health, And The Role Of Camouflaging- Research Gate
Azim Surani, Director of Research at the Gurdon Institute and Professor Emeritus at University of Cambridge, received the Kyoto Prize in Basic Sciences, specifically in the field of Life Sciences and Medicine, for his work in demonstrating how male and female mammalian genomes receive distinct imprints during germ cell development. Genomic imprinting introduced a novel concept to Mendelian genetics and is a now fundamental principle in the life sciences. Surani's research has contributed to developmental biology and epigenetics, along with a wide range of life science fields including physiology, regenerative medicine, reproductive medicine, and plant science. Series: "Kyoto Prize Symposium" [Science] [Show ID: 41117]
Azim Surani, Director of Research at the Gurdon Institute and Professor Emeritus at University of Cambridge, received the Kyoto Prize in Basic Sciences, specifically in the field of Life Sciences and Medicine, for his work in demonstrating how male and female mammalian genomes receive distinct imprints during germ cell development. Genomic imprinting introduced a novel concept to Mendelian genetics and is a now fundamental principle in the life sciences. Surani's research has contributed to developmental biology and epigenetics, along with a wide range of life science fields including physiology, regenerative medicine, reproductive medicine, and plant science. Series: "Kyoto Prize Symposium" [Science] [Show ID: 41117]
Azim Surani, Director of Research at the Gurdon Institute and Professor Emeritus at University of Cambridge, received the Kyoto Prize in Basic Sciences, specifically in the field of Life Sciences and Medicine, for his work in demonstrating how male and female mammalian genomes receive distinct imprints during germ cell development. Genomic imprinting introduced a novel concept to Mendelian genetics and is a now fundamental principle in the life sciences. Surani's research has contributed to developmental biology and epigenetics, along with a wide range of life science fields including physiology, regenerative medicine, reproductive medicine, and plant science. Series: "Kyoto Prize Symposium" [Science] [Show ID: 41117]
Azim Surani, Director of Research at the Gurdon Institute and Professor Emeritus at University of Cambridge, received the Kyoto Prize in Basic Sciences, specifically in the field of Life Sciences and Medicine, for his work in demonstrating how male and female mammalian genomes receive distinct imprints during germ cell development. Genomic imprinting introduced a novel concept to Mendelian genetics and is a now fundamental principle in the life sciences. Surani's research has contributed to developmental biology and epigenetics, along with a wide range of life science fields including physiology, regenerative medicine, reproductive medicine, and plant science. Series: "Kyoto Prize Symposium" [Science] [Show ID: 41117]
Azim Surani, Director of Research at the Gurdon Institute and Professor Emeritus at University of Cambridge, received the Kyoto Prize in Basic Sciences, specifically in the field of Life Sciences and Medicine, for his work in demonstrating how male and female mammalian genomes receive distinct imprints during germ cell development. Genomic imprinting introduced a novel concept to Mendelian genetics and is a now fundamental principle in the life sciences. Surani's research has contributed to developmental biology and epigenetics, along with a wide range of life science fields including physiology, regenerative medicine, reproductive medicine, and plant science. Series: "Kyoto Prize Symposium" [Science] [Show ID: 41117]
2. Flores discusses the Clovis culture'srapid expansion and its role in the American extinction of large mammals. While climate played a part, overhunting and genomic isolationlikely triggered these disappearances. (2)1908
In this episode, our previous guest Dr. Daphne Martschenko returns with her co-author Dr. Sam Trejo to discuss their new book What We Inherit: How New Technologies and Old Myths Are Shaping Our Genomic Future.Dr. Martschenko is an Assistant Professor at the Stanford Center for Biomedical Ethics, where she studies how to promote ethical and socially responsible conduct in human genetics and engages the public around controversial science. Dr. Trejo is an Assistant Professor of Sociology at Princeton University whose work examines how social and biological factors jointly influence human development, with a focus on educational and health inequality.Their collaboration began in graduate school, where they approached genomic research from different intellectual traditions. Dr. Trejo, trained at Stanford, became involved with researchers studying polygenic scores, which are genetic indices linked to social and behavioral outcomes. A controversial talk and an unfortunate reply‑all email situation sparked debate about whether this work risked echoing eugenic ideas. His advisor encouraged him to connect with Dr. Martschenko.Dr. Martschenko, who earned her PhD at Cambridge, was studying how genomic scientists understood their motivations, responsibilities, and the risks of their work. More skeptical of the field's claims and concerned about premature industry applications, she, like Dr. Trejo, was frustrated by polarized academic debates in which opposing sides rarely engaged productively. Their shared desire for more constructive dialogue shaped their collaboration and ultimately their book. In this work, they discovered more common ground than expected. Although disagreements remained, that didn't hinder their ability to think together about regulatory frameworks that should be in place.They highlight two myths that distort public understanding of genomics: • The Destiny Myth—the belief that genes unilaterally determine life outcomes, historically used to justify harms such as involuntary sterilization. • The Race Myth—the false idea that humanity is divided into discrete biological races whose genetic differences explain behavioral or social outcomes, a misconception that has fueled discriminatory policies and continues to underlie white supremacist ideologies.Their work aims to help the public interpret genomic data and understand both its promise and limits. They note that polygenic scores remain a “black box”: even when predictive in certain contexts, their biological pathways are unclear and may operate differently across environments. Their remaining differences center on how scientific advances might counter—or inadvertently reinforce—social harms, and where scientific effort should be focused to meaningfully reduce health disparities.Find their book here: https://press.princeton.edu/books/hardcover/9780691237756/what-we-inherit?srsltid=AfmBOoppBsKJ5iKykfO2MzqGseQw_3EF028_8tMTrAB9G0trgMdqIUSeOther joint publications: https://pubmed.ncbi.nlm.nih.gov/35047864/https://pubmed.ncbi.nlm.nih.gov/37695009/https://pubmed.ncbi.nlm.nih.gov/34493865/
With the increasing incidence of colorectal cancer in those less than 50 years of age, one must wonder how many patients present with a Stage IV diagnosis. Take a deep dive with us discussing the management of metastatic colorectal cancer by joining our team and guests, Drs. Cathy Eng, Michael D'Angelica, and Nina Sanford.Hosts: - Dr. Janet Alvarez - General Surgery Resident at New York Medical College/Metropolitan Hospital Center- Dr. Wini Zambare – General Surgery Resident at Weill Cornell Medical Center/New York Presbyterian- Dr. Philip Bauer, Assistant Professor of Surgery, Division of Colon and Rectal Surgery, The Ohio State University Wexner Medical Center, Arthur G. James Cancer Hospital- Dr. J. Joshua Smith MD, PhD, Chair, Department of Colon and Rectal Surgery at MD Anderson Cancer Center Guest Speakers:- Dr. Michael D'Angelica MD, FACS – Hepatopancreatobiliary Surgery, Memorial Sloan Kettering Cancer Center, Enid A. Haupt Chair in Surgery, Vice Chair, Education- Dr. Cathy Eng MD, FACP - Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, David H. Johnson Endowed Chair in Surgical and Medical Oncology, Professor of Medicine, Hematology and Oncology, VICC Associate Director for Strategic Relations and Research Partnerships, Executive Director, Young Adult Cancers Program - Dr. Nina Sanford, MD – Radiation Oncology, UT Southwestern Medical Center, Chief of Gastrointestinal Radiation Oncology Service, Associate Professor Learning Objectives:1. Review the epidemiology, prognosis, and common metastatic patterns of metastatic colorectal cancer (mCRC).2. Discuss the role of systemic chemotherapy and targeted therapies in the first- and subsequent-line treatment of mCRC, including the impact of molecular biomarkers such as MSI/MMR, RAS, BRAF, and HER2.3. Evaluate the indications and timing of surgical and locoregional therapies for metastatic colorectal cancer, particularly in patients with liver-limited or oligometastatic disease.4. Describe the multidisciplinary management of mCRC, including the roles of radiation therapy, systemic therapy sequencing, and palliative interventions to optimize outcomes and quality of life.References:Singh, M., Morris, V. K., Bandey, I. N., Hong, D. S. & Kopetz, S. Advancements in combining targeted therapy and immunotherapy for colorectal cancer. Trends Cancer 10, 598–609 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38821852/Napolitano, S. et al. BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives. Cancer Treat. Rev. 134, (2025). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40009904/Ciardiello, F. et al. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA. Cancer J. Clin. 72, 372–401 (2022). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/35472088/Kim, S. Y. & Kim, T. W. Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer. ESMO Open 5, e000634 (2020). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/32188714/Biller, L. H. & Schrag, D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA 325, 669–685 (2021). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/33591350/Smith, J. J. et al. Genomic stratification beyond Ras/B-Raf in colorectal liver metastasis patients treated with hepatic arterial infusion. Cancer Med. 8, 6538–6548 (2019). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/31503397/Saadat, L. V. et al. Hepatic Artery Infusion Chemotherapy Compared to Transarterial Radioembolization For Unresectable Colorectal Liver Metastases. Ann. Surg. 10.1097/SLA.0000000000006851 doi:10.1097/SLA.0000000000006851. PubMed Link: https://pubmed.ncbi.nlm.nih.gov/?term=10.1097/SLA.0000000000006851 (Linked via DOI search as the direct PMID is still indexing)Xiao, A. & Fakih, M. KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer. Clin. Colorectal Cancer 23, 199–206 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38825433/André, T. et al. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer. N. Engl. J. Med. 383, 2207–2218 (2020). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/33264544/Morris, V. K. et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J. Clin. Oncol. 41, 678–700 (2023). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/36252154/Xu, Z. et al. Treatments for Stage IV Colon Cancer and Overall Survival. J. Surg. Res. 242, 47–54 (2019). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/31071604/Smith, J. J. & D'Angelica, M. I. Surgical Management of Hepatic Metastases of Colorectal Cancer. Hematol. Oncol. Clin. North Am. 29, 61–84 (2015). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/25475573/Strickler, J. H. et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 24, 496–508 (2023). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/37142372/Kruijssen, D. E. W. van der et al. Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group. Ann. Oncol. 35, 769–779 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38852675/Hitchcock, K. E., Romesser, P. B. & Miller, E. D. Local Therapies in Advanced Colorectal Cancer. Hematol. Oncol. Clin. North Am. 36, 553–567 (2022). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/35562258/Hitchcock, K. E. et al. Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur). BMC Cancer 24, 201 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38350888/Adam, R. et al. Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial. The Lancet 404, 1107–1118 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/39306468/Elez, E. et al. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer. N. Engl. J. Med. 392, 2425–2437 (2025). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40444708/***Fellowship Application Link: https://forms.gle/QSUrR2GWHDZ1MmWC6Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US
In this explainer episode, we've asked Georgia Chan, Senior Data Wrangler at Genomics England, to explain what de-identified data is. You can also find a series of short videos explaining some of the common terms you might encounter about genomics on our YouTube channel. If you've got any questions, or have any other topics you'd like us to explain, let us know on podcast@genomicsengland.co.uk. You can download the transcript or read it below. Florence: What do we mean by de-identified data? My name is Florence Cornish, and today I'm here with Georgia Chan. Georgia is Senior Data Wrangler here at Genomics England, which just means that she cleans up and adds structure to complicated data so that it becomes usable, and she is going to be telling us much more about the topic of de-identified data. Georgia, I think it would be a good place to start by talking about the National Genomic Research Library, which is the library that we at Genomics England store data in. So maybe you could explain more about that and what kind of data is in there. Georgia: Sure. Thanks Florence. So, we have genomic data. Genomic data is information that comes from a person's DNA. It helps us understand how the body works and why disease happens. This can include whole genome sequencing data, variants found in genes, small differences that make each of us unique, and information about how genes function or how they differ between people. Genomic data does not include a person's name or who they are. It's biological information, not identity, and it's used to understand health and disease. It's really important to note that by nature, it's nature, genomic information is incredibly rich. We all have millions of common genetic variants, but your whole genome is unique to you. So although genomic data alone can't directly identify you, it still counts as personal data under data protection. We also have clinical data. Clinical data provides real world context for the genomic data. It shows what's happening in someone's health. This can include diagnosis of a disease or a symptom, treatments that have been received, health outcomes over time, such as remission or progression, and this clinical data that help researchers see how genetic differences relate to symptoms, treatment response, and long-term outcomes. So, we have both of these kinds of data. Genomic data on its own can be hard to interpret, and clinical data on its own only tells part of the story. Together, they allow researchers to better understand how diseases develop, helps them discover new or more targeted treatments, and it helps them improve diagnosis, care, and outcomes. And this is why both types of this data are used together in the National Genomic Research Library. Florence: And so, both of these data types, both clinical and genomic, we say that they are de-identified. But what exactly does that mean? Georgia: Yes, good question. De-identified data means that information which directly identifies a person has been changed or removed from a health record before researchers can access it. And in practice, it means that researchers cannot see who the person is. The data cannot be used to contact individuals, and a person's identity is protected by design, which means that necessary safeguards are embedded into every stage of a service or process. So, researchers work with the data, but not with people's identities. Florence: Could you tell me a little bit more about why it's so important to de-identify data in this way? Georgia: Sure. De-identification creates a safe middle ground. It means that data can be used to improve healthcare whilst people's privacy and trust is respected. So, without de-identification, every new research question would require individual contact and large-scale, long-term research would be extremely difficult. With de-identification, we reduce the risk of someone being identified. We prevent inappropriate use of data, and we ensure that data is used only for approved research. And it's important to note also that it sits alongside a list of other safeguards, so that helps ensure data is used responsibly, such as secure Research Environment, strict access control, independent ethical and governance approvals. And all of those safeguards are provided in Genomics England's Research Environment. Florence: I think a common question that people might have, or a question that I definitely had when I first heard the term, is how de-identified data is different from anonymous data. Georgia: Yes, it is a good question. So, anonymised data cannot be linked back to an individual and is no longer considered personal data, whereas de-identified anonymised data, it has identified as hidden from researchers, but it can still be relinked by a trusted authorised organisation if needed. So, in healthcare research, de-identification is often preferred because it allows long-term follow up. It also allows updates as new health information becomes available, and also allows corrections or withdrawals when they occur and when they're appropriate. Florence: So say a researcher did find something in the data that they might want to feedback, how can we re-identify that participant? What does that process look like? Georgia: Researchers cannot re-identify participants themselves. At Genomics England, if researchers do make a new discovery that could help an individual, for example, a possible diagnosis for a rare condition, we have an in-house clinical team who can link back to that individual's details and work with their NHS clinicians to establish if this new insight can be fed back. So if something clinically important is discovered, research is reported through a formal governance process, and then a trusted authorized team, not the researchers who re-identify the participant, and this ensures that researchers never know who the participant is and individuals remain protected. Whilst important findings can still benefit patients, and this would only happen when it's ethically approved and clinically appropriate. Florence: Great. Well, I think we'll finish there. Thank you so much, Georgia, for taking the time to talk us through the meaning of de-identified data and why it is so important to protect participants. Georgia: Thank you, Flo. And let's remember that de-identified data isn't about hiding information. It's about using it responsibly. Florence: Absolutely. If you want to hear more explainer episodes like this, you can find them on our website at www.genomicsengland.co.uk or wherever you get your podcasts. Thank you for listening.
Amy LeBlanc, DVM, a board-certified veterinary oncologist, Senior Scientist, and the Director of the intramural NCI's Comparative Oncology Program, will review canine osteosarcoma and the clinical, biologic, and molecular features that make it a relevant animal-patient model for humans. She will share new data from the NCI's Comparative Oncology Program regarding MYC, and its value as a predictive biomarker for the disease in canine patients.Dr. Amy LeBlanc is a board-certified veterinary oncologist, Senior Scientist, and the Director of the intramural NCI's Comparative Oncology Program. In this position, she conducts preclinical mouse and translational pet dog studies that are designed to inform the drug and imaging agent development path for human cancer patients, specifically those with osteosarcoma. She directly oversees the NCI Comparative Oncology Trials Consortium (COTC), which provides the infrastructure necessary to connect participating veterinary academic institutions with stakeholders in drug development to execute fit-for-purpose comparative clinical trials in novel therapeutics and imaging agents. Her program provides support to several extramural NCI-funded initiatives, including the Integrated Canine Data Commons and Cancer Moonshot-funded canine immunotherapeutic clinical trials conducted under the PRECINCT network.
Are aliens real? Are they here?Did they create us? What is the evidence that the answer to all three is YES? How do we even process this information if it's true?These are just some of the questions I asked Bruce Fenton in our extraordinary two-hour conversation recorded a few minutes ago.This one lingers. Hope you enjoy it! What's your first reaction—mind blown, skeptical, or already rethinking everything?
Join us in this episode as we explore the transformative role of technology, especially AI, in aging well. Our guest, Jon Warner, a seasoned expert in healthcare and innovation for older adults, shares his journey, latest trends, and a hopeful vision for the future of personalized, preventative care that empowers individuals to thrive at any age.About JonJon Warner is an aging expert and sought-after advisor for digital health, health, healthcare and wellness organizations. Five-time company CEO, Jon is a widely respected entrepreneur having founded and led 3 startups (with 2 successful exits).His career started in the corporate world with Air Products and Chemicals, working in the US and across Europe before joining Exxon-Mobil. Following his 15 years in the corporate world, Warner founded and grew The Worldwide Centerfor Organizational Development, a management consulting business with global clients including Ford Motor Company, L'Oreal, British Airways, HSBC, Microsoft, Glaxo, Foster Wheeler, Toyota, Johnson and Johnson, Coca-Cola, PWC, The UK NHS, Roche and MasterCard.Key TakeawaysIn the past two decades, macro demographic changes have led to increased innovation and more focus on aging populations.Aging is plastic, not predetermined: Aging is a flexible process, influenced by lifestyle and epigenetic factors.Innovation in AI allows us to customize solutions and tailor them in ways that will help us to thrive and to prevail for longer in better health. AI is capable of pulling together data and creating new threads of insights.AI brings the opportunity to case-assess more richly and not only understand the care that's being rendered, but in what context the person lives. Using AI in affordable housing allows analysis of social determinants of health data—answering questions like: Does beingsocial and having a wide friend set prevent heart disease and dementiaAI needs contextual thinking provided by humans The risk of AI is misinformation from scaping the internet, which is not always reliable. We need “guidelines and guide rails.” To reduce risk, be specific with prompts and rely on credible reports and studies.Precision medicine eliminates a one-size-fits-all approach. Genomic data and social determinant data allows us to render solutions that are individualized in ways we couldn't imagine a decade ago.
Genetic resilience and the dynamics of inbreeding and diversity in dairy breeding. Dr. Maltecca (6:43)The main issues in managing genetic diversity in dairy cattle include inbreeding depression and continuing selection without exhausting the available variability in the population. These are difficult to investigate in a breeding population, as there is not a model algorithm where there is the luxury of designing an experiment. Dairy cattle closely resemble one another, so it is difficult to distinguish between the effect of selection from the effect of drift and the effect of deleterious mutation accumulation in the population. Researchers find proxies to estimate inbreeding and inbreeding depression because we don't have good estimates of dominance effects.Identifying genetic diversity within indigenous and highly commercialized breeds for improved performance and future preservation. Dr. Huson (12:24)Dr. Huson covered four steps of thinking about genetic diversity in cattle: characterization of the genetic diversity, biological understanding of why we should preserve diversity, utilizing our understanding of diversity in breeding programs, and preserving and reassessing diversity over time. Harnessing indigenous African breeds for sustainable dairy production: Opportunities for crossbreeding to accelerate genetic improvement. Dr. Mapholi (16:52)Dr. Mapholi emphasized the importance of tick and disease resistance for the sustainability of the African dairy industry. The indigenous African breeds had been overlooked due to small frame size and the perception they were not suitable for commercial farming, but they have excellent tick and disease resistance. Exotic breeds from the US and Europe struggled with the harsh environment. Crossbreeding indigenous and exotic breeds is allowing for simultaneous improvement in milk production and disease resistance. Genomics is particularly helpful to identify the best candidate breeds for crossing.Genomic- versus pedigree-based inbreeding: 2 sides of the same coin. Dr. Macciotta (24:19)It was thought that genomic selection would help in slowing the increase of inbreeding because we were looking at the DNA of the animal, not their pedigree. However, the traditional top animals were the population from which genomic selection began, and genomic selection shortens generation interval, so inbreeding continues to increase at a faster rate. Genomics offer new tools for investigating inbreeding, but there are 10-15 options to calculate inbreeding, all of which could provide a different answer. With pedigree selection, there is only one measurement of inbreeding. We are still investigating the best method for calculating inbreeding using genomic tools.Managing genetic diversity: Strategies for sustainable livestock improvement. Dr. Baes (27:53)Genomic selection has increased the speed at which animals become more related. There are negative implications of inbreeding, but today, the genetic and economic gains achieved through the current intense directional selection still far outweigh the inbreeding issues. No one knows where the edge of the cliff is, however. Dr. Baes envisions an international system one day where academia, AI companies, and producers all work together to understand and manage genetic diversity in livestock.The panelists discuss key takeaways they got from the other speakers' presentations and give perspectives on the topic of genetic diversity for their particular country and field of study. (34:58)Panelists share their take-home thoughts. (46:10)Please subscribe and share with your industry friends to invite more people to join us at the Real Science Exchange virtual pub table. If you want one of our Real Science Exchange t-shirts, screenshot your rating, review, or subscription, and email a picture to anh.marketing@balchem.com. Include your size and mailing address, and we'll mail you a shirt.
Genomic epidemiology is reshaping how we detect, investigate, and control infectious disease outbreaks—but what does that actually look like from the bench to public health? In this episode of Let's Talk Micro, Luis is joined by genomic epidemiologist Krisandra Allen for a practical, case-based conversation on how pathogen sequencing data is generated, analyzed, and paired with epidemiologic information to answer questions traditional methods can't. They discuss foodborne and hepatitis A outbreaks, geographically dispersed clusters, and how sequencing is being integrated into routine public health workflows, while highlighting the essential role of clinical microbiology labs in specimen submission and data quality. A timely episode for microbiologists, public health professionals, and trainees curious about how their lab work feeds into real-world surveillance and outbreak response. Stay connected with Let's Talk Micro: Website: letstalkmicro.com Questions or feedback? Email me at letstalkmicro@outlook.com Interested in being a guest on Let's Talk Micro? Fill out the form here: https://forms.gle/V2fT3asjfyusmqyi8 Support the podcast: Venmo Buy me a Ko-fi
Guest: Dan Flores. Flores details the Clovis culture's rapid expansion and efficient hunting, arguing human predation and genomic meltdown drove the "American extinction" of large mammals like mammoths.1908
The New World Order, Agenda 2030, Agenda 2050, The Great Reset and Rise of The 4IR
Intelligence Notes:LAWSUIT: Genomic Warfare Confirmed-Monsanto Technology in your COVID SHOTS 2026- New World Order.Pharmaceutical Warfare: Bayer, ModeRNA, Pfizer et al.To support the [Show] and its [Research] with Donations, please send all funds and gifts to :$aigner2019 (cashapp) or https://www.paypal.me/Aigner2019 or Zelle (1-617-821-3168). Shalom Aleikhem!
Can genomic classifiers close the gap between what we see and what a tumor will do? In this episode of BackTable Urology, Dr. Carissa Chu (UCSF) joins Dr. Ruchika Talwar (Vanderbilt) to explore how genomic classifiers are reshaping the way clinicians diagnose and manage bladder cancer. --- This podcast is supported by: VeracyteVeracyte.com/decipher-bladder --- SYNPOSIS They discuss the limitations of traditional staging systems and how molecular subtyping is providing deeper insight into tumor biology, treatment response, and prognosis. Dr. Chu highlights where these classifiers can be integrated into real-world clinical decision-making today, where the evidence is still emerging, and which ongoing trials may define the next era of precision medicine in urologic oncology. --- TIMESTAMPS 0:00 - Introduction3:01 - Overview of Genomic Classifiers9:34 - Risk Stratification15:22 - Current Evidence for Genomic Classifiers22:07 - Clinical Implications of Biomarkers27:23 - Ordering Genomic Classifiers33:46 - Future Directions37:57 - Final Takeaways --- RESOURCES Alignment of molecular subtypes across multiple bladder cancer subtyping classifiershttps://pubmed.ncbi.nlm.nih.gov/38480079/ GUSTO Trialhttps://fundingawards.nihr.ac.uk/award/NIHR128103
Send us a textDr. Pankaj Agrawal, Division Chief of Neonatology at University of Miami, discusses rapid genomic advances—from six-month diagnostic timelines in 2000 to same-day sequencing today. While current practice targets phenotype-based testing for unexplained conditions or dysmorphic features, Agrawal advocates moving toward universal NICU sequencing to identify previously unrecognized conditions. Key barriers include administrative buy-in, cost concerns, consent processes, and result disclosure challenges. Even negative results provide value—offering families reassurance and contributing to research databases. With only 5,000 of 20,000 genes linked to human disease, ongoing gene discovery work continues. Agrawal emphasizes the NICU as ideal for genomic implementation given high genetic disease prevalence and intervention opportunities. Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!
Watch every episode ad-free & uncensored on Patreon: https://patreon.com/dannyjones Dr. Melissa Ilardo, Ph.D is a professor of evolutionary genomics and biomedical informatics at the University of Utah. Her research explores human evolution and adaptation in populations that have previously been overlooked or excluded from biological research. Her recent work looks into a population who engages in the practice of breath-hold diving & is evolving on a unique breakaway trajectory from the rest of homo sapiens on earth. SPONSORS https://hellofresh.com/danny10fm - Get 10 Free Meals + a Free breakfast for Life! https://cell.ver.so/danny - Use code DANNY to save 15% on your first order. https://butcherbox.com/danny - Get free steak in every box for a year PLUS $20 off your first box. https://whiterabbitenergy.com/?ref=DJP - Use code DJP for 20% off EPISODE LINKS https://medicine.utah.edu/faculty/melissa-ilardo https://www.superhumanlab.org https://www.nytimes.com/2018/04/19/science/bajau-evolution-ocean-diving.html https://www.instagram.com/superhumanscilab https://linkedin.com/in/melissa-ilardo FOLLOW DANNY JONES https://www.instagram.com/dannyjones https://twitter.com/jonesdanny OUTLINE 00:00 - Genomic evolution of Baju people (sea nomads) 15:00 - How long Baju can hold their breath for 21:19 - All-female Korean free divers (Haenyeo) 32:17 - Lost species of humans 42:44 - Humans won't survive the next 100,000 years 47:50 - Mother of humanity: The real "Eve" 59:48 - Humans are attracted to mates by pheromones 01:06:30 - Why assisted reproductive technology might be harmful to evolution 01:14:57 - Effects of the global population mixing & mating together 01:21:37 - Risks of CRISPR gene editing 01:30:37 - Lifespan & the grandmother hypothesis 01:37:18 - Evolution of un-contacted indigenous tribes 01:40:50 - What future humans will look like 01:49:08 - Intelligence is not genetic Learn more about your ad choices. Visit podcastchoices.com/adchoices
Today's guest is Dr. Mark Kiel, Chief Science Officer and Founder at Genomenon. Genomenon is a genomics intelligence company that unlocks real-world evidence from biomedical literature to help pharmaceutical and clinical diagnostics companies inform precision medicine, accelerate patient diagnosis, and guide trial design and label expansion. Mark joins Emerj Editorial Director Matthew DeMello to explore how AI can streamline the extraction, organization, and interpretation of genomic and clinical data, enabling faster, more accurate decision-making in pharmaceutical R&D. He also shares practical approaches to integrating AI with human curation, improving workflow efficiency, and scaling insights for rare disease diagnosis, trial design, and drug development strategy. This episode is sponsored by Genomenon. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the 'AI in Business' podcast!
In this crossover episode with the Functional Breeding Podcast Sarah and friend of the pod Dr Hekman discuss a recent paper revealing some interesting differences between the brains of herding dogs and “normal” dogs, particularly Sarah's beloved border collies. The paper is "Genomic evidence for behavioral adaptation of herding dogs." and you can find it here: https://www.science.org/doi/full/10.1126/sciadv.adp4591 Sign up for courses and join the membership here: sarahstremming.com Join us on Patreon: https://www.patreon.com/cogdogradio Music by AlexGrohl from Pixabay
Ancestral Native American Dispersal and Admixture 3. Meltzer describes the dispersal of the first peoples into the Americas, explaining that ancestral Native Americans likely arrived first and made it south of the ice sheets, splitting into Northern and Southern groups with the Southern group dispersing rapidly toward Tierra del Fuego. This rapid dispersal into completely unknown, people-free land suggests dogs—whose genomic history matches human travel—were likely part of their cultural repertoire for defense and hunting. Genomic data reveals that ancient groups later became isolated, developing distinctive genetic markers before experiencing later admixture as mobility increased, and critically shows no ancestral relationship between these first Americans and European, Ainu, or Polynesian populations.
Get started with 1 month free of Superhuman today, using my link: https://try.sprh.mn/briankeating Today's guest made bacteria immune to every virus that exists. This breakthrough could revolutionize medicine by creating virus proof cell therapies and potentially extending this protection to human cells. Also demonstrating that we can fundamentally rewrite the language of life itself, something that was previously thought impossible. George Church is a Harvard Medical School genetics professor and pioneer of synthetic biology. He's an entrepreneur who's found in multiple biotech companies and is known for pushing the boundaries between science fiction and reality. His team just did something that sounds like pure science fiction. They made living cells completely immune to every virus on Earth. That resistant immune, every single virus that tries to infect your cells just fails. The viruses can't evolve around it. Here's the wild part. They didn't add anything new. They just removed a few letter from the genetic alphabet. But George isn't stopping there. He wants to do this to human cells. He's talking about engineering astronauts for Mars missions, bringing back wooly mammoths, and maybe even, just maybe, making humans virus proof to the implications are staggering. The ethics are murky. And the timeline. Well, if church's track record tells us anything is happening far faster than we think. KEY TAKEAWAYS 00:00:00 – Church's team made cells virus-proof, a major medical breakthrough 00:02:34 – Radiation resistance may come from DNA repair linked to desiccation 00:04:43 – A few genes can boost bacteria's radiation resistance 00:07:16 – Panspermia is unlikely due to harsh space conditions 00:10:50 – Space travel may need biological, not just physical, changes 00:14:19 – Regenesis explores synthetic biology's potential 00:18:19 – Height involves many genes, but single ones can have big effects 00:20:57 – Once sci-fi, genome sequencing and pig organs are now real 00:23:20 – Church and Venter are more collaborators than rivals 00:27:17 – Rewriting genes can create virus-proof organisms 00:35:36 – DNA can store data, but reading/writing is slow 00:41:06 – Gattaca and Jurassic Park portray genetics well with small flaws 00:44:03 – Gene therapies can be affordable for all 00:46:44 – Stem cells can create any body cell for therapy 00:49:15 – “Mirror humans” are possible but avoided ethically 00:53:59 – Genomic privacy isn't an issue since we shed DNA constantly 00:56:09 – Gene editing helps endangered species adapt, not revive extinct ones 01:00:30 – Virus-proof humans are possible, but tough to deliver to all cells 01:02:59 – Gene therapies could reverse aging at the cellular level 01:04:18 – Church avoids saying “impossible,” but admits to timeline optimism - Get My NEW Book: Focus Like a Nobel Prize Winner: https://www.amazon.com/dp/B0FN8DH6SX?ref_=pe_93986420_775043100 Please join my mailing list here
Part 2 of this installment of Unearthed! features animals, swords, art, shoes, shipwrecks, and the miscellany category of potpourri. Research: Abrams, G., Auguste, P., Pirson, S. et al. Earliest evidence of Neanderthal multifunctional bone tool production from cave lion (Panthera spelaea) remains. Sci Rep 15, 24010 (2025). https://doi.org/10.1038/s41598-025-08588-w Addley, Esther. “English warship sunk in 1703 storm gives up its secrets three centuries on.” The Guardian. 7/31/2025. https://www.theguardian.com/science/2025/jul/31/british-warship-hms-northumberland-1703-storm-archaeology Alberge, Dalya. “New research may rewrite origins of the Book of Kells, says academic.” The Guardian. 9/26/2025. https://www.theguardian.com/books/2025/sep/26/new-research-may-rewrite-origins-of-the-book-of-kells-says-academic Alex, Bridget et al. “Regional disparities in US media coverage of archaeology research.” Science Advances. Vol. 11, No. 27. July 2025. https://www.science.org/doi/10.1126/sciadv.adt5435 American Historical Association. “Historians Defend the Smithsonian.” Updated 8/15/2015. https://www.historians.org/news/historians-defend-the-smithsonian/#statement Anderson, Sonja. “Underwater Archaeologists Capture Photos of Japanese Warship That Hasn’t Been Seen Since It Sank During World War II.” Smithsonian. 7/23/2025. https://www.smithsonianmag.com/smart-news/underwater-archaeologists-capture-photos-of-japanese-warship-that-hasnt-been-seen-since-it-sank-during-world-war-ii-180987026/ “Ancient DNA provides a new means to explore ancient diets.” Via PhysOrg. 7/1/2025. https://phys.org/news/2025-06-ancient-dna-explore-diets.html Archaeology Magazine. “Roman Workshop Specialized in Manufacturing Nails.” 9/11/2025. https://archaeology.org/news/2025/09/11/roman-workshop-specialized-in-manufacturing-nails-for-army-boots/ Arnold, Paul. “DNA analysis reveals insights into Ötzi the Iceman's mountain neighbors.” Phys.org. 7/22/2025. https://phys.org/news/2025-07-dna-analysis-reveals-insights-tzi.html Arnold, Paul. “Prehistoric 'Swiss army knife' made from cave lion bone discovered in Neanderthal cave.” Phys.org. 7/9/2025. https://phys.org/news/2025-07-prehistoric-swiss-army-knife-cave.html Associated Press. “Divers recover artifacts from the Titanic’s sister ship Britannic for the first time.” 9/16/2025. https://apnews.com/article/britannic-titanic-shipwreck-recovery-9a525f9831bc0d67c1c9604cc7155765 Breen, Kerry. “Woman's remains exhumed in Oregon's oldest unidentified person case.” CBS News. 9/24/2025. https://www.cbsnews.com/news/oak-grove-jane-doe-remains-exhumed-oregon-unidentified-person-homicide/ Croze, M., Paladin, A., Zingale, S. et al. Genomic diversity and structure of prehistoric alpine individuals from the Tyrolean Iceman’s territory. Nat Commun 16, 6431 (2025). https://doi.org/10.1038/s41467-025-61601-8 Davis, Nicola. “Even Neanderthals had distinct preferences when it came to making dinner, study suggests.” The Guardian. 7/17/2025. https://www.theguardian.com/science/2025/jul/17/even-neanderthals-had-distinct-preferences-when-it-came-to-making-dinner-study-suggests Durham University. “Bronze and Iron Age cultures in the Middle East were committed to wine production.” EurekAlert. 9/17/2025. https://www.eurekalert.org/news-releases/1098278 “Archaeologists discover four at-risk shipwrecks on colonial waterfront at Brunswick Town/Fort Anderson State Historic Site.” 8/4/2025. https://news.ecu.edu/2025/08/04/archaeologists-discover-four-at-risk-shipwrecks-on-colonial-waterfront-at-brunswick-town-fort-anderson-state-historic-site/ Fratsyvir, Anna. “Polish president-elect urges Ukraine to allow full exhumations of Volyn massacre victims, despite resumed work.” 7/12/2025. https://kyivindependent.com/polands-president-elect-urges-zelensky-to-allow-full-exhumations-in-volyn-as-work-already-resumes/ Fry, Devin and Jordan Gartner. “Coroner’s office identifies man 55 years later after exhuming his body from cemetery.” 7/19/2025. https://www.kltv.com/2025/07/19/coroners-office-identifies-man-55-years-later-after-exhuming-his-body-cemetery/ Guagnin, Maria et al. “12,000-year-old rock art marked ancient water sources in Arabia's desert.” Phys.org. 10/1/2025. https://phys.org/news/2025-10-year-art-ancient-sources-arabia.html History Blog. “Medieval leather goods found in Oslo.” 7/15/2025. https://www.thehistoryblog.com/archives/73641 Jana Matuszak, Jana. “Of Captive Storm Gods and Cunning Foxes: New Insights into Early Sumerian Mythology, with an Editoin of Ni 12501.” Iraq. Vol. 86. https://www.cambridge.org/core/journals/iraq/article/of-captive-storm-gods-and-cunning-foxes-new-insights-into-early-sumerian-mythology-with-an-edition-of-ni-12501/391CFC6A9361C23A0E7AF159F565A911 Kuta, Sarah. “Cut Marks on Animal Bones Suggest Neanderthal Groups Had Their Own Unique Culinary Traditions.” Smithsonian. 7/17/2025. https://www.smithsonianmag.com/smart-news/cut-marks-on-animal-bones-suggest-neanderthal-groups-had-their-own-unique-culinary-traditions-180987002/ Kuta, Sarah. “Seventy Years Later, They Finally Know What It Is.” Smithsonian. 8/1/2025. https://www.smithsonianmag.com/smart-news/scientists-found-sticky-goo-inside-a-2500-year-old-jar-70-years-later-they-finally-know-what-it-is-180987088/ Kuta, Sarah. “Underwater Archaeologists Were Looking for a Lost Shipwreck in Wisconsin. They Stumbled Upon a Different Vessel Instead.” Smithsonian. 7/16/2025. https://www.smithsonianmag.com/smart-news/underwater-archaeologists-were-looking-for-a-lost-shipwreck-in-wisconsin-they-stumbled-upon-a-different-vessel-instead-180986990/ Linköping University. “Ancient crop discovered in the Canary Islands thanks to archaeological DNA.” Phys.org. https://phys.org/news/2025-09-ancient-crop-canary-islands-archaeological.html Lucchesi, Madison. “More layoffs at GBH as ‘Defunded’ sign goes viral.” Boston.com. 7/24/2025. https://www.boston.com/news/media/2025/07/24/gbh-layoffs-defunded-sign/ Luscombe, Richard. “‘It’s incredibly exciting’: ancient canoe unearthed after Hurricane Ian stormed through Florida.” The Guardian. 9/28/2025. https://www.theguardian.com/us-news/2025/sep/28/florida-ancient-canoes Margalida, Antoni et al. “The Bearded Vulture as an accumulator of historical remains: Insights for future ecological and biocultural studies.” Ecology. Volume 106, Issue 9. 9/11/2025. https://esajournals.onlinelibrary.wiley.com/doi/10.1002/ecy.70191 Metcalfe, Tom. “300-year-old pirate-plundered shipwreck that once held 'eyewatering treasure' discovered off Madagascar.” Live Science. 7/3/2025. https://www.livescience.com/archaeology/300-year-old-pirate-plundered-shipwreck-that-once-held-eyewatering-treasure-discovered-off-madagascar Mondal, Sanjukta. “Ancient Romans likely used extinct sea creature fossils as amulets.” Phys.org. 7/28/2025. https://phys.org/news/2025-07-ancient-romans-extinct-sea-creature.html Morris, Steven. “Iron age settlement found in Gloucestershire after detectorist unearths Roman swords.” The Guardian. 7/4/2025. https://www.theguardian.com/science/2025/jul/04/roman-swords-gloucestershire-villa-iron-age-settlement-discovery Mullett, Russell et al. “Precious finger traces from First Nations ancestors revealed in a glittering mountain cave in Australia.” Phys.org. 7/28/2025. https://phys.org/news/2025-07-precious-finger-nations-ancestors-revealed.html Ocean Exploration Trust. “Expedition reveals 13 shipwrecks from WWII battles off Guadalcanal.” Phys.org. 8/4/2025. https://phys.org/news/2025-08-reveals-shipwrecks-wwii-guadalcanal.html Oster, Sandee. “Study translates fragmentary ancient Sumerian myth around 4,400 years old.” Phys.org. 7/22/2025. https://phys.org/news/2025-07-fragmentary-ancient-sumerian-myth-years.html Paul, Andrew. “130-year-old butter bacteria discovered in Danish basement.” Popular Science. 9/15/2025. https://www.popsci.com/science/old-butter-basement-discovery/ Penn, Tim. “Big Roman shoes discovered near Hadrian's Wall—but they don't necessarily mean big Roman feet.” Phys.org. 7/20/2025. https://phys.org/news/2025-07-big-roman-hadrian-wall-dont.html#google_vignette Pogrebin, Robin and Graham Bowley. “Smithsonian Responds to Trump’s Demand for a Review of Its Exhibits.” New York Times. 9/3/2025. https://www.nytimes.com/2025/09/03/arts/design/smithsonian-bunch-trump.html Preston, Elizabeth. “Scientists found a 650-year-old shoe in a vulture nest. That’s just the start of it.’ National Geographic. 10/1/2025. https://www.nationalgeographic.com/animals/article/vulture-nest-was-hiding-a-650-year-old-shoe Reilly, Adam. “GBH lays off 13 staff at American Experience, pauses production of new documentaries.” GBH. 7/22/2025. https://www.wgbh.org/news/local/2025-07-22/gbh-lays-off-13-staff-at-american-experience-pauses-production-of-new-documentaries Richmond, Todd. “Searchers discover ‘ghost ship’ that sank in Lake Michigan almost 140 years ago.” Associated Press. 9/15/2025. https://apnews.com/article/lake-michigan-schooner-shipwreck-door-county-ccff930d8cd87f3597483938f8fb4fd6 Savat, Sarah. “Discovery expands understanding of Neolithic agricultural practices, diets in East Asia.” EurekAlert. 9/24/2025. https://www.eurekalert.org/news-releases/1099662 Seb Falk, James Wade, The Lost Song of Wade: Peterhouse 255 Revisited, The Review of English Studies, Volume 76, Issue 326, October 2025, Pages 339–365, https://doi.org/10.1093/res/hgaf038 Smith, Kiona N. “Oldest wooden tools in East Asia may have come from any of three species.” Ars Technica. 7/7/2025. https://arstechnica.com/science/2025/07/did-denisovans-or-homo-erectus-make-the-oldest-wooden-tools-in-east-asia/ The Catholic Herald. “Plans in train to exhume holy remains of martyr St Thomas More.” 7/14/2025. https://thecatholicherald.com/article/plans-in-train-to-exhume-holy-remains-of-martyr-st-thomas-more The History Blog. “1600-year-old iron scale, weights found in Turkey.” 7/10/2025. https://www.thehistoryblog.com/archives/73597 The History Blog. “2,500-year-old honey identified in ancient offering.” 7/31/2025. https://www.thehistoryblog.com/archives/73776 The History Blog. “Kushan vessel inscribed with woman’s name found in Tajikistan.” 7/8/2025. https://www.thehistoryblog.com/archives/73582 The History Blog. “Medieval sword fished out of Vistula in Warsaw.” 7/7/2025. https://www.thehistoryblog.com/archives/73574 The History Blog. “Unique 3D mural 3,000-4,000 years old found in Peru.” 7/30/2025. https://www.thehistoryblog.com/archives/73769 The White House. “Letter to the Smithsonian: Internal Review of Smithsonian Exhibitions and Materials.” 8/12/2025. https://www.whitehouse.gov/briefings-statements/2025/08/letter-to-the-smithsonian-internal-review-of-smithsonian-exhibitions-and-materials/ Thorsberg, Christian. “A Tiny Typo May Explain a Centuries-Old Mystery About Chaucer’s ‘Canterbury Tales’ and ‘Troilus and Criseyde’.” Smithsonian. 7/16/2025. https://www.smithsonianmag.com/smart-news/a-tiny-typo-may-explain-a-centuries-old-mystery-about-chaucers-canterbury-tales-and-troilus-and-criseyde-180986991/ University of Cambridge. “Scholars just solved a 130-year literary mystery—and it all hinged on one word.” 7/16/2025. https://www.sciencedaily.com/releases/2025/07/250716000855.htm Vindolanda Trust. “Magna Shoes.” 7/2/2025. https://www.vindolanda.com/news/magna-shoes Whiddington, Richard. “$2 Thrift Store Plate Turns Out to Be Rare Chinese Porcelain Worth Thousands.” Artnet. 8/21/2025. https://news.artnet.com/market/chinese-porcelain-uk-thrift-store-auction-2680013 Whiddington, Richard. “Famed Antikythera Shipwreck Yields More Astonishing Discoveries.” Artnet News. 7/16/2025. https://news.artnet.com/art-world/antikythera-shipwreck-more-discoveries-2668217 Whiddington, Richard. “Scholars Crack 130-Year-Old Mystery Behind a Lost Medieval Epic.” 7/17/2025. https://news.artnet.com/art-world/song-of-wade-mystery-chaucer-2668558 Whiddington, Richard. “Sunken Clues Reveal Identity of Mysterious Scottish Shipwreck.” Artnet. 7/25/2025. https://news.artnet.com/art-world/scotland-shipwreck-sanday-2671342 See omnystudio.com/listener for privacy information.
Part one of this quarter's installment of Unearthed! features things related to books and letters, and edibles and potables, and as we usually do, we are starting this installment of Unearthed with updates. Research: Abrams, G., Auguste, P., Pirson, S. et al. Earliest evidence of Neanderthal multifunctional bone tool production from cave lion (Panthera spelaea) remains. Sci Rep 15, 24010 (2025). https://doi.org/10.1038/s41598-025-08588-w Addley, Esther. “English warship sunk in 1703 storm gives up its secrets three centuries on.” The Guardian. 7/31/2025. https://www.theguardian.com/science/2025/jul/31/british-warship-hms-northumberland-1703-storm-archaeology Alberge, Dalya. “New research may rewrite origins of the Book of Kells, says academic.” The Guardian. 9/26/2025. https://www.theguardian.com/books/2025/sep/26/new-research-may-rewrite-origins-of-the-book-of-kells-says-academic Alex, Bridget et al. “Regional disparities in US media coverage of archaeology research.” Science Advances. Vol. 11, No. 27. July 2025. https://www.science.org/doi/10.1126/sciadv.adt5435 American Historical Association. “Historians Defend the Smithsonian.” Updated 8/15/2015. https://www.historians.org/news/historians-defend-the-smithsonian/#statement Anderson, Sonja. “Underwater Archaeologists Capture Photos of Japanese Warship That Hasn’t Been Seen Since It Sank During World War II.” Smithsonian. 7/23/2025. https://www.smithsonianmag.com/smart-news/underwater-archaeologists-capture-photos-of-japanese-warship-that-hasnt-been-seen-since-it-sank-during-world-war-ii-180987026/ “Ancient DNA provides a new means to explore ancient diets.” Via PhysOrg. 7/1/2025. https://phys.org/news/2025-06-ancient-dna-explore-diets.html Archaeology Magazine. “Roman Workshop Specialized in Manufacturing Nails.” 9/11/2025. https://archaeology.org/news/2025/09/11/roman-workshop-specialized-in-manufacturing-nails-for-army-boots/ Arnold, Paul. “DNA analysis reveals insights into Ötzi the Iceman's mountain neighbors.” Phys.org. 7/22/2025. https://phys.org/news/2025-07-dna-analysis-reveals-insights-tzi.html Arnold, Paul. “Prehistoric 'Swiss army knife' made from cave lion bone discovered in Neanderthal cave.” Phys.org. 7/9/2025. https://phys.org/news/2025-07-prehistoric-swiss-army-knife-cave.html Associated Press. “Divers recover artifacts from the Titanic’s sister ship Britannic for the first time.” 9/16/2025. https://apnews.com/article/britannic-titanic-shipwreck-recovery-9a525f9831bc0d67c1c9604cc7155765 Breen, Kerry. “Woman's remains exhumed in Oregon's oldest unidentified person case.” CBS News. 9/24/2025. https://www.cbsnews.com/news/oak-grove-jane-doe-remains-exhumed-oregon-unidentified-person-homicide/ Croze, M., Paladin, A., Zingale, S. et al. Genomic diversity and structure of prehistoric alpine individuals from the Tyrolean Iceman’s territory. Nat Commun 16, 6431 (2025). https://doi.org/10.1038/s41467-025-61601-8 Davis, Nicola. “Even Neanderthals had distinct preferences when it came to making dinner, study suggests.” The Guardian. 7/17/2025. https://www.theguardian.com/science/2025/jul/17/even-neanderthals-had-distinct-preferences-when-it-came-to-making-dinner-study-suggests Durham University. “Bronze and Iron Age cultures in the Middle East were committed to wine production.” EurekAlert. 9/17/2025. https://www.eurekalert.org/news-releases/1098278 “Archaeologists discover four at-risk shipwrecks on colonial waterfront at Brunswick Town/Fort Anderson State Historic Site.” 8/4/2025. https://news.ecu.edu/2025/08/04/archaeologists-discover-four-at-risk-shipwrecks-on-colonial-waterfront-at-brunswick-town-fort-anderson-state-historic-site/ Fratsyvir, Anna. “Polish president-elect urges Ukraine to allow full exhumations of Volyn massacre victims, despite resumed work.” 7/12/2025. https://kyivindependent.com/polands-president-elect-urges-zelensky-to-allow-full-exhumations-in-volyn-as-work-already-resumes/ Fry, Devin and Jordan Gartner. “Coroner’s office identifies man 55 years later after exhuming his body from cemetery.” 7/19/2025. https://www.kltv.com/2025/07/19/coroners-office-identifies-man-55-years-later-after-exhuming-his-body-cemetery/ Guagnin, Maria et al. “12,000-year-old rock art marked ancient water sources in Arabia's desert.” Phys.org. 10/1/2025. https://phys.org/news/2025-10-year-art-ancient-sources-arabia.html History Blog. “Medieval leather goods found in Oslo.” 7/15/2025. https://www.thehistoryblog.com/archives/73641 Jana Matuszak, Jana. “Of Captive Storm Gods and Cunning Foxes: New Insights into Early Sumerian Mythology, with an Editoin of Ni 12501.” Iraq. Vol. 86. https://www.cambridge.org/core/journals/iraq/article/of-captive-storm-gods-and-cunning-foxes-new-insights-into-early-sumerian-mythology-with-an-edition-of-ni-12501/391CFC6A9361C23A0E7AF159F565A911 Kuta, Sarah. “Cut Marks on Animal Bones Suggest Neanderthal Groups Had Their Own Unique Culinary Traditions.” Smithsonian. 7/17/2025. https://www.smithsonianmag.com/smart-news/cut-marks-on-animal-bones-suggest-neanderthal-groups-had-their-own-unique-culinary-traditions-180987002/ Kuta, Sarah. “Seventy Years Later, They Finally Know What It Is.” Smithsonian. 8/1/2025. https://www.smithsonianmag.com/smart-news/scientists-found-sticky-goo-inside-a-2500-year-old-jar-70-years-later-they-finally-know-what-it-is-180987088/ Kuta, Sarah. “Underwater Archaeologists Were Looking for a Lost Shipwreck in Wisconsin. They Stumbled Upon a Different Vessel Instead.” Smithsonian. 7/16/2025. https://www.smithsonianmag.com/smart-news/underwater-archaeologists-were-looking-for-a-lost-shipwreck-in-wisconsin-they-stumbled-upon-a-different-vessel-instead-180986990/ Linköping University. “Ancient crop discovered in the Canary Islands thanks to archaeological DNA.” Phys.org. https://phys.org/news/2025-09-ancient-crop-canary-islands-archaeological.html Lucchesi, Madison. “More layoffs at GBH as ‘Defunded’ sign goes viral.” Boston.com. 7/24/2025. https://www.boston.com/news/media/2025/07/24/gbh-layoffs-defunded-sign/ Luscombe, Richard. “‘It’s incredibly exciting’: ancient canoe unearthed after Hurricane Ian stormed through Florida.” The Guardian. 9/28/2025. https://www.theguardian.com/us-news/2025/sep/28/florida-ancient-canoes Margalida, Antoni et al. “The Bearded Vulture as an accumulator of historical remains: Insights for future ecological and biocultural studies.” Ecology. Volume 106, Issue 9. 9/11/2025. https://esajournals.onlinelibrary.wiley.com/doi/10.1002/ecy.70191 Metcalfe, Tom. “300-year-old pirate-plundered shipwreck that once held 'eyewatering treasure' discovered off Madagascar.” Live Science. 7/3/2025. https://www.livescience.com/archaeology/300-year-old-pirate-plundered-shipwreck-that-once-held-eyewatering-treasure-discovered-off-madagascar Mondal, Sanjukta. “Ancient Romans likely used extinct sea creature fossils as amulets.” Phys.org. 7/28/2025. https://phys.org/news/2025-07-ancient-romans-extinct-sea-creature.html Morris, Steven. “Iron age settlement found in Gloucestershire after detectorist unearths Roman swords.” The Guardian. 7/4/2025. https://www.theguardian.com/science/2025/jul/04/roman-swords-gloucestershire-villa-iron-age-settlement-discovery Mullett, Russell et al. “Precious finger traces from First Nations ancestors revealed in a glittering mountain cave in Australia.” Phys.org. 7/28/2025. https://phys.org/news/2025-07-precious-finger-nations-ancestors-revealed.html Ocean Exploration Trust. “Expedition reveals 13 shipwrecks from WWII battles off Guadalcanal.” Phys.org. 8/4/2025. https://phys.org/news/2025-08-reveals-shipwrecks-wwii-guadalcanal.html Oster, Sandee. “Study translates fragmentary ancient Sumerian myth around 4,400 years old.” Phys.org. 7/22/2025. https://phys.org/news/2025-07-fragmentary-ancient-sumerian-myth-years.html Paul, Andrew. “130-year-old butter bacteria discovered in Danish basement.” Popular Science. 9/15/2025. https://www.popsci.com/science/old-butter-basement-discovery/ Penn, Tim. “Big Roman shoes discovered near Hadrian's Wall—but they don't necessarily mean big Roman feet.” Phys.org. 7/20/2025. https://phys.org/news/2025-07-big-roman-hadrian-wall-dont.html#google_vignette Pogrebin, Robin and Graham Bowley. “Smithsonian Responds to Trump’s Demand for a Review of Its Exhibits.” New York Times. 9/3/2025. https://www.nytimes.com/2025/09/03/arts/design/smithsonian-bunch-trump.html Preston, Elizabeth. “Scientists found a 650-year-old shoe in a vulture nest. That’s just the start of it.’ National Geographic. 10/1/2025. https://www.nationalgeographic.com/animals/article/vulture-nest-was-hiding-a-650-year-old-shoe Reilly, Adam. “GBH lays off 13 staff at American Experience, pauses production of new documentaries.” GBH. 7/22/2025. https://www.wgbh.org/news/local/2025-07-22/gbh-lays-off-13-staff-at-american-experience-pauses-production-of-new-documentaries Richmond, Todd. “Searchers discover ‘ghost ship’ that sank in Lake Michigan almost 140 years ago.” Associated Press. 9/15/2025. https://apnews.com/article/lake-michigan-schooner-shipwreck-door-county-ccff930d8cd87f3597483938f8fb4fd6 Savat, Sarah. “Discovery expands understanding of Neolithic agricultural practices, diets in East Asia.” EurekAlert. 9/24/2025. https://www.eurekalert.org/news-releases/1099662 Seb Falk, James Wade, The Lost Song of Wade: Peterhouse 255 Revisited, The Review of English Studies, Volume 76, Issue 326, October 2025, Pages 339–365, https://doi.org/10.1093/res/hgaf038 Smith, Kiona N. “Oldest wooden tools in East Asia may have come from any of three species.” Ars Technica. 7/7/2025. https://arstechnica.com/science/2025/07/did-denisovans-or-homo-erectus-make-the-oldest-wooden-tools-in-east-asia/ The Catholic Herald. “Plans in train to exhume holy remains of martyr St Thomas More.” 7/14/2025. https://thecatholicherald.com/article/plans-in-train-to-exhume-holy-remains-of-martyr-st-thomas-more The History Blog. “1600-year-old iron scale, weights found in Turkey.” 7/10/2025. https://www.thehistoryblog.com/archives/73597 The History Blog. “2,500-year-old honey identified in ancient offering.” 7/31/2025. https://www.thehistoryblog.com/archives/73776 The History Blog. “Kushan vessel inscribed with woman’s name found in Tajikistan.” 7/8/2025. https://www.thehistoryblog.com/archives/73582 The History Blog. “Medieval sword fished out of Vistula in Warsaw.” 7/7/2025. https://www.thehistoryblog.com/archives/73574 The History Blog. “Unique 3D mural 3,000-4,000 years old found in Peru.” 7/30/2025. https://www.thehistoryblog.com/archives/73769 The White House. “Letter to the Smithsonian: Internal Review of Smithsonian Exhibitions and Materials.” 8/12/2025. https://www.whitehouse.gov/briefings-statements/2025/08/letter-to-the-smithsonian-internal-review-of-smithsonian-exhibitions-and-materials/ Thorsberg, Christian. “A Tiny Typo May Explain a Centuries-Old Mystery About Chaucer’s ‘Canterbury Tales’ and ‘Troilus and Criseyde’.” Smithsonian. 7/16/2025. https://www.smithsonianmag.com/smart-news/a-tiny-typo-may-explain-a-centuries-old-mystery-about-chaucers-canterbury-tales-and-troilus-and-criseyde-180986991/ University of Cambridge. “Scholars just solved a 130-year literary mystery—and it all hinged on one word.” 7/16/2025. https://www.sciencedaily.com/releases/2025/07/250716000855.htm Vindolanda Trust. “Magna Shoes.” 7/2/2025. https://www.vindolanda.com/news/magna-shoes Whiddington, Richard. “$2 Thrift Store Plate Turns Out to Be Rare Chinese Porcelain Worth Thousands.” Artnet. 8/21/2025. https://news.artnet.com/market/chinese-porcelain-uk-thrift-store-auction-2680013 Whiddington, Richard. “Famed Antikythera Shipwreck Yields More Astonishing Discoveries.” Artnet News. 7/16/2025. https://news.artnet.com/art-world/antikythera-shipwreck-more-discoveries-2668217 Whiddington, Richard. “Scholars Crack 130-Year-Old Mystery Behind a Lost Medieval Epic.” 7/17/2025. https://news.artnet.com/art-world/song-of-wade-mystery-chaucer-2668558 Whiddington, Richard. “Sunken Clues Reveal Identity of Mysterious Scottish Shipwreck.” Artnet. 7/25/2025. https://news.artnet.com/art-world/scotland-shipwreck-sanday-2671342 See omnystudio.com/listener for privacy information.
As it was in the Garden of Eden, where the serpent changed the biological makeup of God's creation, so it goes again with the Fallen Ones using mad science to create an abomination on Earth. Genomic technologies are driving a vast expansion in digitalized data, from gene sequences and entire genomes that link genes to specific functions and other types of metadata for humans, other animals, plants, and microbes. A prime example includes the development of customized bioweapons. America's adversaries can direct biological attacks, specifically at US livestock and crops, to create a food security crisis. Another way is for the harvesting and pirating of DNA for racial targeting. Humanity is at a crossroads. It has to avoid both biotechnological calamity and the reign of the Antichrist. Listen to Ground Zero with Clyde Lewis M-F from 7-10 pm, pacific time on groundzeroplus.com. Call in to the LIVE show at 503-225-0860. #groundzeroplus #clydelewis #genome #DNA #biological
© 2020-2026 Ivy Podcast Discovery LLC
